Master bibliography — melanoma

Last curated: 2026-09-01

Coverage: 636 unique PubMed records cited across the 26 wiki pages and literature artefacts. Every PMID below was retrieved live from PubMed E-utilities during the 2026-09-01 build or independent audit, and the complete final set was re-resolved in a clean verification pass at the end of the audit. A bibliography line asserts that the record exists, that its citation is as written, and that it is cited by the listed pages or literature artefacts.

Sections group records by the page cluster that first cites them; a record cited by several clusters appears once, in the first.

Foundations, epidemiology and global burden

• Adamson AS, et al. Association of UV Radiation Exposure, Diagnostic Scrutiny, and Melanoma Incidence in US Counties. JAMA internal medicine. 2022;182:1181-9. PMID 36190719 — tags: [epidemiology-and-global-burden, overview, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, overview.md, screening-and-overdiagnosis.md
• Adamson AS, et al. Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. JAMA dermatology. 2022;158:426-431. PMID 35293957 — tags: [epidemiology-and-global-burden, overview, red-flags-and-safety-concerns, risk-factors-and-prevention, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, overview.md, red-flags-and-safety-concerns.md, risk-factors-and-prevention.md, screening-and-overdiagnosis.md
• Aggarwal P, et al. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. Journal of the American Academy of Dermatology. 2021;85:388-395. PMID 33852922 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Aitken JF, et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995-2014. International journal of cancer. 2018;142:1528-1535. PMID 29105744 — tags: [epidemiology-and-global-burden, overview, risk-factors-and-prevention] — cited by: epidemiology-and-global-burden.md, overview.md, risk-factors-and-prevention.md
• Arnold M, et al. Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA dermatology. 2022;158:495-503. PMID 35353115 — tags: [epidemiology-and-global-burden, overview, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, overview.md, screening-and-overdiagnosis.md
• Atkins MB, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41:186-197. PMID 36166727 — tags: [brain-metastases, cellular-therapy-and-resistance, immunotherapy-advanced-disease, overview, targeted-therapy] — cited by: brain-metastases.md, cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md, overview.md, targeted-therapy.md
• Atkins MB, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999;17:2105-16. PMID 10561265 — tags: [cellular-therapy-and-resistance, overview] — cited by: cellular-therapy-and-resistance.md, overview.md
• Bai X, et al. Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. The British journal of dermatology. 2022;187:401-410. PMID 35293617 — tags: [acral-and-mucosal-melanoma, guidelines, overview, special-populations] — cited by: acral-and-mucosal-melanoma.md, guidelines.md, overview.md, special-populations.md
• Berk-Krauss J, et al. New Systematic Therapies and Trends in Cutaneous Melanoma Deaths Among US Whites, 1986-2016. American journal of public health. 2020;110:731-733. PMID 32191523 — tags: [epidemiology-and-global-burden, overview] — cited by: epidemiology-and-global-burden.md, overview.md
• Bishop KD, et al. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. International journal of cancer. 2014;134:2961-71. PMID 24272143 — tags: [acral-and-mucosal-melanoma, epidemiology-and-global-burden, overview, uveal-melanoma] — cited by: acral-and-mucosal-melanoma.md, epidemiology-and-global-burden.md, overview.md, uveal-melanoma.md
• Bjørch MF, et al. Overdiagnosis in malignant melanoma: a scoping review. BMJ evidence-based medicine. 2024;29:17-28. PMID 37793786 — tags: [overview, screening-and-overdiagnosis] — cited by: overview.md, screening-and-overdiagnosis.md
• Blank CU, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. The New England journal of medicine. 2024;391:1696-1708. PMID 38828984 — tags: [adjuvant-therapy, clinical-trials-landscape, guidelines, neoadjuvant-therapy, overview, surgical-management-and-margins] — cited by: adjuvant-therapy.md, clinical-trials-landscape.md, guidelines.md, neoadjuvant-therapy.md, overview.md, surgical-management-and-margins.md
• Blazek K, et al. The impact of skin cancer prevention efforts in New South Wales, Australia: Generational trends in melanoma incidence and mortality. Cancer epidemiology. 2022;81:102263. PMID 36174452 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Brunsgaard EK, et al. Melanoma in skin of color: Part I. Epidemiology and clinical presentation. Journal of the American Academy of Dermatology. 2023;89:445-456. PMID 35533771 — tags: [acral-and-mucosal-melanoma, epidemiology-and-global-burden, patient-experience-and-advocacy, red-flags-and-safety-concerns, special-populations] — cited by: acral-and-mucosal-melanoma.md, epidemiology-and-global-burden.md, patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md, special-populations.md
• Bucchi L, et al. Mid-term trends and recent birth-cohort-dependent changes in incidence rates of cutaneous malignant melanoma in Italy. International journal of cancer. 2021;148:835-844. PMID 33405292 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161:1681-96. PMID 26091043 — tags: [molecular-subtypes-and-genomics, overview, targeted-therapy, uveal-melanoma] — cited by: molecular-subtypes-and-genomics.md, overview.md, targeted-therapy.md, uveal-melanoma.md
• Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. The New England journal of medicine. 2011;364:2507-16. PMID 21639808 — tags: [overview, targeted-therapy] — cited by: overview.md, targeted-therapy.md
• Clarke CA, et al. Continued Increase in Melanoma Incidence across all Socioeconomic Status Groups in California, 1998-2012. The Journal of investigative dermatology. 2017;137:2282-2290. PMID 28736233 — tags: [epidemiology-and-global-burden, overview, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, overview.md, screening-and-overdiagnosis.md
• Coart E, et al. Evaluating the potential of relapse-free survival as a surrogate for overall survival in the adjuvant therapy of melanoma with checkpoint inhibitors. European journal of cancer (Oxford, England : 1990). 2020;137:171-174. PMID 32777716 — tags: [adjuvant-therapy, guidelines, overview] — cited by: adjuvant-therapy.md, guidelines.md, overview.md
• Crystal JS, et al. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. JAMA surgery. 2022;157:835-842. PMID 35921122 — tags: [clinical-trials-landscape, overview, sentinel-node-and-nodal-management, surveillance-and-survivorship] — cited by: clinical-trials-landscape.md, overview.md, sentinel-node-and-nodal-management.md, surveillance-and-survivorship.md
• DE Gruijl FR, et al. Cutaneous Melanoma: Sheep in Wolves Clothing?. Anticancer research. 2022;42:5021-5025. PMID 36191966 — tags: [epidemiology-and-global-burden, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, screening-and-overdiagnosis.md
• De Pinto G, et al. Global trends in cutaneous malignant melanoma incidence and mortality. Melanoma research. 2024;34:265-275. PMID 38391175 — tags: [epidemiology-and-global-burden, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, screening-and-overdiagnosis.md
• Di Carlo V, et al. Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3). JNCI cancer spectrum. 2020;4:pkaa078. PMID 33409455 — tags: [epidemiology-and-global-burden, special-populations, staging] — cited by: epidemiology-and-global-burden.md, special-populations.md, staging.md
• Didier AJ, et al. Patterns and trends in melanoma mortality in the United States, 1999-2020. BMC cancer. 2024;24:790. PMID 38956559 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Du Z, et al. Global Burden and Trends of Cutaneous Malignant Melanoma in the Elderly Population: Analysis of Global Burden of Disease Study 2021. Clinical, cosmetic and investigational dermatology. 2025;18:3429-3442. PMID 41425115 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Eggermont AMM, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology. 2021;22:643-654. PMID 33857412 — tags: [adjuvant-therapy, overview] — cited by: adjuvant-therapy.md, overview.md
• Faries MB, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. The New England journal of medicine. 2017;376:2211-2222. PMID 28591523 — tags: [adjuvant-therapy, clinical-trials-landscape, guidelines, overview, red-flags-and-safety-concerns, sentinel-node-and-nodal-management, surgical-management-and-margins, surveillance-and-survivorship] — cited by: adjuvant-therapy.md, clinical-trials-landscape.md, guidelines.md, overview.md, red-flags-and-safety-concerns.md, sentinel-node-and-nodal-management.md, surgical-management-and-margins.md, surveillance-and-survivorship.md
• Gandini S, et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. European journal of cancer (Oxford, England : 1990). 2005;41:28-44. PMID 15617989 — tags: [overview, risk-factors-and-prevention] — cited by: overview.md, risk-factors-and-prevention.md
• Garbe C, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. European journal of cancer (Oxford, England : 1990). 2025;215:115152. PMID 39700658 — tags: [brain-metastases, clinical-diagnosis-and-dermoscopy, epidemiology-and-global-burden, guidelines, molecular-subtypes-and-genomics, screening-and-overdiagnosis, staging, surveillance-and-survivorship] — cited by: brain-metastases.md, clinical-diagnosis-and-dermoscopy.md, epidemiology-and-global-burden.md, guidelines.md, molecular-subtypes-and-genomics.md, screening-and-overdiagnosis.md, staging.md, surveillance-and-survivorship.md
• Gonzalez-Cao M, et al. Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2026;28:645-653. PMID 40841506 — tags: [acral-and-mucosal-melanoma, overview] — cited by: acral-and-mucosal-melanoma.md, overview.md
• Hanna S, et al. Surgical excision margins in primary cutaneous melanoma: A systematic review and meta-analysis. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2021;47:1558-1574. PMID 33722422 — tags: [overview, surgical-management-and-margins] — cited by: overview.md, surgical-management-and-margins.md
• Helgadottir H, et al. Melanoma Incidence and Mortality Trends Among Patients Aged 59 Years or Younger in Sweden. JAMA dermatology. 2024;160:1201-1210. PMID 39245436 — tags: [epidemiology-and-global-burden, overview, special-populations] — cited by: epidemiology-and-global-burden.md, overview.md, special-populations.md
• Helkkula T, et al. Acral Melanoma Incidence and Survival Trends in 1990-2020: A Nationwide, Population-based Study. Acta dermato-venereologica. 2024;104:adv40242. PMID 39140487 — tags: [acral-and-mucosal-melanoma, epidemiology-and-global-burden, overview] — cited by: acral-and-mucosal-melanoma.md, epidemiology-and-global-burden.md, overview.md
• Hida T, et al. Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan. Cancer medicine. 2024;13:e70360. PMID 39564955 — tags: [acral-and-mucosal-melanoma, molecular-subtypes-and-genomics, overview] — cited by: acral-and-mucosal-melanoma.md, molecular-subtypes-and-genomics.md, overview.md
• Huang J, et al. Global Incidence, Mortality, Risk Factors and Trends of Melanoma: A Systematic Analysis of Registries. American journal of clinical dermatology. 2023;24:965-975. PMID 37296344 — tags: [epidemiology-and-global-burden, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, screening-and-overdiagnosis.md
• Hübner J, et al. Population Skin Cancer Screening and Melanoma Mortality Rates. JAMA dermatology. 2026;162:775-779. PMID 42268621 — tags: [guidelines, overview, screening-and-overdiagnosis] — cited by: guidelines.md, overview.md, screening-and-overdiagnosis.md
• Ives NJ, et al. Adjuvant interferon-α for the treatment of high-risk melanoma: An individual patient data meta-analysis. European journal of cancer (Oxford, England : 1990). 2017;82:171-183. PMID 28692949 — tags: [adjuvant-therapy, overview] — cited by: adjuvant-therapy.md, overview.md
• Kanaki T, et al. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. European journal of cancer (Oxford, England : 1990). 2019;119:18-29. PMID 31401470 — tags: [adjuvant-therapy, guidelines, overview, staging] — cited by: adjuvant-therapy.md, guidelines.md, overview.md, staging.md
• Kao SZ, et al. Economic burden of skin cancer treatment in the USA: an analysis of the Medical Expenditure Panel Survey Data, 2012-2018. Cancer causes & control : CCC. 2023;34:205-212. PMID 36449145 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Kirkwood JM, et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nature medicine. 2023;29:2835-2843. PMID 37845511 — tags: [adjuvant-therapy, clinical-trials-landscape, immune-related-adverse-events, overview] — cited by: adjuvant-therapy.md, clinical-trials-landscape.md, immune-related-adverse-events.md, overview.md
• Kleinerman RA, et al. Increased Risk of Skin Cancer in 1,851 Long-Term Retinoblastoma Survivors. The Journal of investigative dermatology. 2021;141:2849-2857.e3. PMID 34153328 — tags: [germline-predisposition, overview, red-flags-and-safety-concerns, special-populations] — cited by: germline-predisposition.md, overview.md, red-flags-and-safety-concerns.md, special-populations.md
• Lal T, et al. Socioeconomic Influences on Melanoma Incidence Patterns by Stage in the US. Journal of surgical oncology. 2025;132:465-472. PMID 40637374 — tags: [epidemiology-and-global-burden, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, screening-and-overdiagnosis.md
• Landi MT, et al. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature genetics. 2020;52:494-504. PMID 32341527 — tags: [acral-and-mucosal-melanoma, germline-predisposition, overview] — cited by: acral-and-mucosal-melanoma.md, germline-predisposition.md, overview.md
• Leiter U, et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:3000-3008. PMID 31557067 — tags: [guidelines, overview, sentinel-node-and-nodal-management, surgical-management-and-margins] — cited by: guidelines.md, overview.md, sentinel-node-and-nodal-management.md, surgical-management-and-margins.md
• Li J, et al. Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review. Therapeutic advances in medical oncology. 2020;12:1758835920922028. PMID 32489431 — tags: [acral-and-mucosal-melanoma, overview] — cited by: acral-and-mucosal-melanoma.md, overview.md
• Liu M, et al. Analysing the causal relationship between potentially protective and risk factors and cutaneous melanoma: A Mendelian randomization study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2024;38:102-111. PMID 37712456 — tags: [overview, risk-factors-and-prevention] — cited by: overview.md, risk-factors-and-prevention.md
• Luke JJ, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. European journal of cancer (Oxford, England : 1990). 2025;220:115381. PMID 40198940 — tags: [adjuvant-therapy, clinical-trials-landscape, immune-related-adverse-events, neoadjuvant-therapy, overview] — cited by: adjuvant-therapy.md, clinical-trials-landscape.md, immune-related-adverse-events.md, neoadjuvant-therapy.md, overview.md
• Mangione CM, et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329:1290-1295. PMID 37071089 — tags: [clinical-trials-landscape, epidemiology-and-global-burden, guidelines, overview, red-flags-and-safety-concerns, screening-and-overdiagnosis, special-populations] — cited by: clinical-trials-landscape.md, epidemiology-and-global-burden.md, guidelines.md, overview.md, red-flags-and-safety-concerns.md, screening-and-overdiagnosis.md, special-populations.md
• Nathan P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. The New England journal of medicine. 2021;385:1196-1206. PMID 34551229 — tags: [overview, uveal-melanoma] — cited by: overview.md, uveal-melanoma.md
• Newell F, et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nature communications. 2019;10:3163. PMID 31320640 — tags: [acral-and-mucosal-melanoma, molecular-subtypes-and-genomics, overview] — cited by: acral-and-mucosal-melanoma.md, molecular-subtypes-and-genomics.md, overview.md
• O'Sullivan DE, et al. Age-specific melanoma incidence trends in Canada. Cancer epidemiology. 2026;102:103062. PMID 41932245 — tags: [epidemiology-and-global-burden, special-populations] — cited by: epidemiology-and-global-burden.md, special-populations.md
• Oh J, et al. Global patterns of melanoma, burden attributable to ultraviolet radiation exposure, and projections to 2050 across 185 countries: A population-based study with global modeling. JAAD international. 2026;27:149-159. PMID 42502459 — tags: [epidemiology-and-global-burden, risk-factors-and-prevention, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, risk-factors-and-prevention.md, screening-and-overdiagnosis.md
• Olateju OA, et al. Marginal health care expenditures for melanoma care in the United States. Journal of managed care & specialty pharmacy. 2024;30:1364-1374. PMID 39612258 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Olivier T, et al. Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial. Translational oncology. 2024;45:101959. PMID 38621314 — tags: [guidelines, neoadjuvant-therapy, overview] — cited by: guidelines.md, neoadjuvant-therapy.md, overview.md
• Olsen CM, et al. Does Sex Matter? Temporal Analyses of Melanoma Trends among Men and Women Suggest Etiologic Heterogeneity. The Journal of investigative dermatology. 2025;145:135-143. PMID 38897542 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Olsen CM, et al. Estimating the attributable fraction for cancer: A meta-analysis of nevi and melanoma. Cancer prevention research (Philadelphia, Pa.). 2010;3:233-45. PMID 20086181 — tags: [overview, risk-factors-and-prevention] — cited by: overview.md, risk-factors-and-prevention.md
• Patrinely JR Jr, et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA oncology. 2021;7:744-748. PMID 33764387 — tags: [immune-related-adverse-events, overview, red-flags-and-safety-concerns, surveillance-and-survivorship] — cited by: immune-related-adverse-events.md, overview.md, red-flags-and-safety-concerns.md, surveillance-and-survivorship.md
• Piulats JM, et al. Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis. Annals of oncology : official journal of the European Society for Medical Oncology. 2024;35:317-326. PMID 38048850 — tags: [immunotherapy-advanced-disease, overview, targeted-therapy, uveal-melanoma] — cited by: immunotherapy-advanced-disease.md, overview.md, targeted-therapy.md, uveal-melanoma.md
• Reinhart JP, et al. Incidence and mortality trends of primary cutaneous melanoma: A 50-year Rochester Epidemiologic Project study. JAAD international. 2024;16:144-154. PMID 38957842 — tags: [epidemiology-and-global-burden, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, screening-and-overdiagnosis.md
• Robert C, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England journal of medicine. 2015;372:30-9. PMID 25399551 — tags: [overview, targeted-therapy] — cited by: overview.md, targeted-therapy.md
• Rohaan MW, et al. Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2022;387:2113-2125. PMID 36477031 — tags: [cellular-therapy-and-resistance, clinical-trials-landscape, overview] — cited by: cellular-therapy-and-resistance.md, clinical-trials-landscape.md, overview.md
• Sacchetto L, et al. Trends in incidence of thick, thin and in situ melanoma in Europe. European journal of cancer (Oxford, England : 1990). 2018;92:108-118. PMID 29395684 — tags: [epidemiology-and-global-burden, overview, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, overview.md, screening-and-overdiagnosis.md
• Schachter J, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet (London, England). 2017;390:1853-1862. PMID 28822576 — tags: [immunotherapy-advanced-disease, overview] — cited by: immunotherapy-advanced-disease.md, overview.md
• Schadendorf D, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015;33:1889-94. PMID 25667295 — tags: [cellular-therapy-and-resistance, immunotherapy-advanced-disease, overview] — cited by: cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md, overview.md
• Schonfeld SJ, et al. Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. British journal of cancer. 2021;124:1312-1319. PMID 33473166 — tags: [germline-predisposition, overview, special-populations] — cited by: germline-predisposition.md, overview.md, special-populations.md
• Shain AH, et al. The Genetic Evolution of Melanoma from Precursor Lesions. The New England journal of medicine. 2015;373:1926-36. PMID 26559571 — tags: [molecular-subtypes-and-genomics, overview, uveal-melanoma] — cited by: molecular-subtypes-and-genomics.md, overview.md, uveal-melanoma.md
• Siegel RL, et al. Cancer statistics, 2026. CA: a cancer journal for clinicians. 2026;76:e70043. PMID 41528114 — tags: [epidemiology-and-global-burden, overview, staging] — cited by: epidemiology-and-global-burden.md, overview.md, staging.md
• Sung H, et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: a cancer journal for clinicians. 2026;76:e70090. PMID 42417444 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Tawbi HA, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. The New England journal of medicine. 2022;386:24-34. PMID 34986285 — tags: [clinical-trials-landscape, immune-related-adverse-events, immunotherapy-advanced-disease, overview] — cited by: clinical-trials-landscape.md, immune-related-adverse-events.md, immunotherapy-advanced-disease.md, overview.md
• Thiam A, et al. Years of life lost due to metastatic melanoma in 12 countries. Journal of medical economics. 2016;19:259-64. PMID 26531249 — tags: [epidemiology-and-global-burden, surveillance-and-survivorship] — cited by: epidemiology-and-global-burden.md, surveillance-and-survivorship.md
• Thomas S, et al. Declining invasive and rising in situ melanoma incidence trends in Iceland: A nationwide cohort study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2025;39:1278-1284. PMID 39444324 — tags: [epidemiology-and-global-burden, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, screening-and-overdiagnosis.md
• Thrift AP, et al. Melanoma Incidence Among Non-Hispanic Whites in All 50 US States From 2001 Through 2015. Journal of the National Cancer Institute. 2020;112:533-539. PMID 31346623 — tags: [epidemiology-and-global-burden, screening-and-overdiagnosis] — cited by: epidemiology-and-global-burden.md, screening-and-overdiagnosis.md
• Utjés D, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. Lancet (London, England). 2019;394:471-477. PMID 31280965 — tags: [overview, surgical-management-and-margins] — cited by: overview.md, surgical-management-and-margins.md
• Van Raamsdonk CD, et al. Mutations in GNA11 in uveal melanoma. The New England journal of medicine. 2010;363:2191-9. PMID 21083380 — tags: [overview, uveal-melanoma] — cited by: overview.md, uveal-melanoma.md
• Wang M, et al. Recent global patterns in skin cancer incidence, mortality, and prevalence. Chinese medical journal. 2025;138:185-192. PMID 39682020 — tags: [epidemiology-and-global-burden] — cited by: epidemiology-and-global-burden.md
• Weinberger Y, et al. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1975-2020). Ocular oncology and pathology. 2025;11:30-36. PMID 40225965 — tags: [clinical-trials-landscape, epidemiology-and-global-burden, overview, uveal-melanoma] — cited by: clinical-trials-landscape.md, epidemiology-and-global-burden.md, overview.md, uveal-melanoma.md
• Wolchok JD, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2025;392:11-22. PMID 39282897 — tags: [clinical-trials-landscape, immunotherapy-advanced-disease, overview, patient-experience-and-advocacy, uveal-melanoma] — cited by: clinical-trials-landscape.md, immunotherapy-advanced-disease.md, overview.md, patient-experience-and-advocacy.md, uveal-melanoma.md
• Yan BY, et al. Survival differences in acral lentiginous melanoma according to socioeconomic status and race. Journal of the American Academy of Dermatology. 2022;86:379-386. PMID 34363907 — tags: [acral-and-mucosal-melanoma, overview, patient-experience-and-advocacy, special-populations] — cited by: acral-and-mucosal-melanoma.md, overview.md, patient-experience-and-advocacy.md, special-populations.md

Risk factors, prevention and germline predisposition

• Allen NC, et al. Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. The New England journal of medicine. 2023;388:804-812. PMID 36856616 — tags: [risk-factors-and-prevention, special-populations] — cited by: risk-factors-and-prevention.md, special-populations.md
• An S, et al. Indoor Tanning and the Risk of Overall and Early-Onset Melanoma and Non-Melanoma Skin Cancer: Systematic Review and Meta-Analysis. Cancers. 2021;13. PMID 34885049 — tags: [red-flags-and-safety-concerns, risk-factors-and-prevention] — cited by: red-flags-and-safety-concerns.md, risk-factors-and-prevention.md
• Avril MF, et al. [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma]. Annales de dermatologie et de venereologie. 2015;142:26-36. PMID 25600792 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Belbasis L, et al. Non-genetic risk factors for cutaneous melanoma and keratinocyte skin cancers: An umbrella review of meta-analyses. Journal of dermatological science. 2016;84:330-339. PMID 27663092 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Bertolotto C, et al. A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature. 2011;480:94-8. PMID 22012259 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Byrne L, et al. Impact of Multigene Panel Testing in High-Risk Uveal Melanoma Patients. Pigment cell & melanoma research. 2026;39:e70108. PMID 42415513 — tags: [germline-predisposition, uveal-melanoma] — cited by: germline-predisposition.md, uveal-melanoma.md
• Chen AC, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. The New England journal of medicine. 2015;373:1618-26. PMID 26488693 — tags: [clinical-trials-landscape, risk-factors-and-prevention] — cited by: clinical-trials-landscape.md, risk-factors-and-prevention.md
• Davies JR, et al. Development and validation of a melanoma risk score based on pooled data from 16 case-control studies. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2015;24:817-24. PMID 25713022 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• De Giorgi V, et al. Cutaneous Melanoma and Occupational UV Exposure: Associations with Anatomical Site, Histological Subtype, and Breslow Thickness. Cancers. 2025;17. PMID 40867334 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Demenais F, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study. Journal of the National Cancer Institute. 2010;102:1568-83. PMID 20876876 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Drozdowski R, et al. Dysplastic nevus part I: Historical perspective, classification, and epidemiology. Journal of the American Academy of Dermatology. 2023;88:1-10. PMID 36038073 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Flores-Torres MH, et al. Hair color, family history of melanoma, and the risk of Parkinson's disease: An analysis update. Parkinsonism & related disorders. 2024;119:105965. PMID 38142631 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Fontanillas P, et al. Disease risk scores for skin cancers. Nature communications. 2021;12:160. PMID 33420020 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Gandini S, et al. Epidemiological evidence of carcinogenicity of sunbed use and of efficacy of preventive measures. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019;33 Suppl 2:57-62. PMID 30811691 — tags: [red-flags-and-safety-concerns, risk-factors-and-prevention] — cited by: red-flags-and-safety-concerns.md, risk-factors-and-prevention.md
• Gandini S, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. European journal of cancer (Oxford, England : 1990). 2005;41:45-60. PMID 15617990 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Gandini S, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. European journal of cancer (Oxford, England : 1990). 2005;41:2040-59. PMID 16125929 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Gao X, et al. Family history of melanoma and Parkinson disease risk. Neurology. 2009;73:1286-91. PMID 19841380 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Gironi LC, et al. Dermatologic surveillance in healthy carriers of CDKN2A and p.E318K MITF germline variants from melanoma-prone families: a 14 years hospital-based experience. Melanoma research. 2025;35:424-428. PMID 40623218 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Goldstein AM, et al. Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals. JAMA dermatology. 2026;162:692-700. PMID 42201696 — tags: [germline-predisposition, red-flags-and-safety-concerns, special-populations, surveillance-and-survivorship] — cited by: germline-predisposition.md, red-flags-and-safety-concerns.md, special-populations.md, surveillance-and-survivorship.md
• Goldstein AM, et al. Prospective risk of cancer in CDKN2A germline mutation carriers. Journal of medical genetics. 2004;41:421-4. PMID 15173226 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Green AC, et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29:257-63. PMID 21135266 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Grossman DC, et al. Behavioral Counseling to Prevent Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319:1134-1142. PMID 29558558 — tags: [guidelines, risk-factors-and-prevention, screening-and-overdiagnosis] — cited by: guidelines.md, risk-factors-and-prevention.md, screening-and-overdiagnosis.md
• Guhan SM, et al. Cancer risks associated with the germline MITF(E318K) variant. Scientific reports. 2020;10:17051. PMID 33051548 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Helgadottir H, et al. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families. Journal of medical genetics. 2014;51:545-52. PMID 24935963 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Henrikson NB, et al. Behavioral Counseling for Skin Cancer Prevention: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2018;319:1143-1157. PMID 29558557 — tags: [patient-experience-and-advocacy, red-flags-and-safety-concerns, risk-factors-and-prevention] — cited by: patient-experience-and-advocacy.md, red-flags-and-safety-concerns.md, risk-factors-and-prevention.md
• Ingold N, et al. Exploring the Germline Genetics of In Situ and Invasive Cutaneous Melanoma: A Genome-Wide Association Study Meta-Analysis. JAMA dermatology. 2024;160:964-971. PMID 39141363 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Johansson PA, et al. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma. Melanoma research. 2019;29:483-490. PMID 31464824 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Kanetsky PA, et al. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?. Cancer. 2010;116:2416-28. PMID 20301115 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Klatte DCF, et al. Pancreatic Cancer Surveillance in Carriers of a Germline CDKN2A Pathogenic Variant: Yield and Outcomes of a 20-Year Prospective Follow-Up. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40:3267-3277. PMID 35658523 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Kraemer KH, et al. Xeroderma Pigmentosum. GeneReviews®. 2003 Jun 20 [updated 2022 Mar 24]. PMID 20301571 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Kwa M, et al. The risk of ultraviolet exposure for melanoma in Fitzpatrick skin types I-IV: A 20-year systematic review with meta-analysis for sunburns. Journal of the European Academy of Dermatology and Venereology : JEADV. 2025;39:1239-1253. PMID 39230206 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Li Y, et al. Childhood sunburn and risk of melanoma and non-melanoma skin cancer: a Mendelian randomization study. Environmental science and pollution research international. 2023;30:122011-122023. PMID 37962759 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Liyanage UE, et al. Is there a causal relationship between vitamin D and melanoma risk? A Mendelian randomization study. The British journal of dermatology. 2020;182:97-103. PMID 31218665 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Lynch HT, et al. Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity. Familial cancer. 2016;15:487-91. PMID 26892865 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Maduka RC, et al. Indoor Versus Outdoor: Does Occupational Sunlight Exposure Increase Melanoma Risk? A Systematic Review. The Journal of surgical research. 2023;283:274-281. PMID 36423476 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Mar V, et al. Predicting melanoma risk for the Australian population. The Australasian journal of dermatology. 2011;52:109-16. PMID 21605094 — tags: [risk-factors-and-prevention, surveillance-and-survivorship] — cited by: risk-factors-and-prevention.md, surveillance-and-survivorship.md
• Overbeek KA, et al. Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants. Journal of medical genetics. 2021;58:264-269. PMID 32482799 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Papadakis K, et al. POT1 genetic testing in melanoma-prone families in Sweden: germline variant prevalence and tumor spectrum in identified carriers. Acta oncologica (Stockholm, Sweden). 2025;64:1102-1108. PMID 40851494 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Paszkowska-Szczur K, et al. Xeroderma pigmentosum genes and melanoma risk. International journal of cancer. 2013;133:1094-100. PMID 23436679 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Pauley K, et al. Considerations for Germline Testing in Melanoma: Updates in Behavioral Change and Pancreatic Surveillance for Carriers of CDKN2A Pathogenic Variants. Frontiers in oncology. 2022;12:837057. PMID 35372037 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Pawlak MT, et al. Legislation restricting access to indoor tanning throughout the world. Archives of dermatology. 2012;148:1006-12. PMID 22801924 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Pissa M, et al. Melanoma-specific survival before and after inclusion in a familial melanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers. Journal of the European Academy of Dermatology and Venereology : JEADV. 2023;37:284-292. PMID 36156317 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Potrony M, et al. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations. JAMA dermatology. 2016;152:405-12. PMID 26650189 — tags: [germline-predisposition, surveillance-and-survivorship] — cited by: germline-predisposition.md, surveillance-and-survivorship.md
• Raimondi S, et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. International journal of cancer. 2008;122:2753-60. PMID 18366057 — tags: [germline-predisposition, risk-factors-and-prevention] — cited by: germline-predisposition.md, risk-factors-and-prevention.md
• Read J, et al. Melanoma genetics. Journal of medical genetics. 2016;53:1-14. PMID 26337759 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Robles-Espinoza CD, et al. POT1 loss-of-function variants predispose to familial melanoma. Nature genetics. 2014;46:478-481. PMID 24686849 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Rodriguez-Acevedo AJ, et al. Indoor tanning prevalence after the International Agency for Research on Cancer statement on carcinogenicity of artificial tanning devices: systematic review and meta-analysis. The British journal of dermatology. 2020;182:849-859. PMID 31381131 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Shih ST, et al. Economic evaluation of skin cancer prevention in Australia. Preventive medicine. 2009;49:449-53. PMID 19747936 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md
• Simonin-Wilmer I, et al. Population-based analysis of POT1 variants in a cutaneous melanoma case-control cohort. Journal of medical genetics. 2023;60:692-696. PMID 36539277 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Taylor NJ, et al. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. Journal of the American Academy of Dermatology. 2019;81:386-394. PMID 30731170 — tags: [germline-predisposition] — cited by: germline-predisposition.md
• Walpole S, et al. Comprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide. Journal of the National Cancer Institute. 2018;110:1328-1341. PMID 30517737 — tags: [germline-predisposition, uveal-melanoma] — cited by: germline-predisposition.md, uveal-melanoma.md
• Zhu Y, et al. Aspirin for the primary prevention of skin cancer: A meta-analysis. Oncology letters. 2015;9:1073-1080. PMID 25663859 — tags: [risk-factors-and-prevention] — cited by: risk-factors-and-prevention.md

Screening, early detection and overdiagnosis

• Adamson AS, et al. Melanoma Overdiagnosis Is Not the Key Problem-Reply. JAMA dermatology. 2022;158:1083-1084. PMID 35895049 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Adamson AS, et al. Screening for Melanoma in Men: a Cost-Effectiveness Analysis. Journal of general internal medicine. 2020;35:1175-1181. PMID 31705474 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Ahnlide I, et al. Validity of ABCD Rule of Dermoscopy in Clinical Practice. Acta dermato-venereologica. 2016;96:367-72. PMID 26351008 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Argenziano G, et al. Seven-point checklist of dermoscopy revisited. The British journal of dermatology. 2011;164:785-90. PMID 21175563 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Aviv B, et al. Comparison of Disease Progression Between Amelanotic Melanoma and Melanotic Melanoma. Pigment cell & melanoma research. 2026;39:e70083. PMID 42087524 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Baade PD, et al. The relationship between melanoma thickness and time to diagnosis in a large population-based study. Archives of dermatology. 2006;142:1422-7. PMID 17116832 — tags: [clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns] — cited by: clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md
• Berwick M, et al. Screening for cutaneous melanoma by skin self-examination. Journal of the National Cancer Institute. 1996;88:17-23. PMID 8847720 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Bibbins-Domingo K, et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316:429-35. PMID 27458948 — tags: [guidelines, screening-and-overdiagnosis] — cited by: guidelines.md, screening-and-overdiagnosis.md
• Breitbart EW, et al. Systematic skin cancer screening in Northern Germany. Journal of the American Academy of Dermatology. 2012;66:201-11. PMID 22074699 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Brinker TJ, et al. Deep neural networks are superior to dermatologists in melanoma image classification. European journal of cancer (Oxford, England : 1990). 2019;119:11-17. PMID 31401469 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Buja A, et al. Cost-effectiveness of a melanoma screening programme using whole disease modelling. Journal of medical screening. 2020;27:157-167. PMID 31711359 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Carli P, et al. Dermatologist detection and skin self-examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Archives of dermatology. 2003;139:607-12. PMID 12756097 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Conway J, et al. Adult and Pediatric Nail Unit Melanoma: Epidemiology, Diagnosis, and Treatment. Cells. 2023;12. PMID 36980308 — tags: [clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns] — cited by: clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md
• Dinnes J, et al. Dermoscopy, with and without visual inspection, for diagnosing melanoma in adults. The Cochrane database of systematic reviews. 2018;12:CD011902. PMID 30521682 — tags: [clinical-diagnosis-and-dermoscopy, screening-and-overdiagnosis] — cited by: clinical-diagnosis-and-dermoscopy.md, screening-and-overdiagnosis.md
• Dinnes J, et al. Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults. The Cochrane database of systematic reviews. 2018;12:CD013190. PMID 30521681 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Elmore JG, et al. Pathologists' diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ (Clinical research ed.). 2017;357:j2813. PMID 28659278 — tags: [histopathology-and-prognostic-factors, red-flags-and-safety-concerns, screening-and-overdiagnosis] — cited by: histopathology-and-prognostic-factors.md, red-flags-and-safety-concerns.md, screening-and-overdiagnosis.md
• Greco ME, et al. Overdiagnosis of Melanoma In Situ. Journal of clinical medicine. 2026;15. PMID 42279200 — tags: [red-flags-and-safety-concerns, screening-and-overdiagnosis] — cited by: red-flags-and-safety-concerns.md, screening-and-overdiagnosis.md
• Greenwald E, et al. Real-world outcomes of melanoma surveillance using the MoleMap NZ telemedicine platform. Journal of the American Academy of Dermatology. 2021;85:596-603. PMID 32114083 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Gualandri L, et al. Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay. Journal of the European Academy of Dermatology and Venereology : JEADV. 2009;23:283-7. PMID 19207640 — tags: [clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns] — cited by: clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md
• Haenssle HA, et al. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists. Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29:1836-1842. PMID 29846502 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Haenssle HA, et al. Seven-point checklist for dermatoscopy: performance during 10 years of prospective surveillance of patients at increased melanoma risk. Journal of the American Academy of Dermatology. 2010;62:785-93. PMID 20226567 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Haggenmüller S, et al. Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts. European journal of cancer (Oxford, England : 1990). 2021;156:202-216. PMID 34509059 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Hübner J, et al. [Skin cancer screening in Germany: review after ten years]. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61:1536-1543. PMID 30411137 — tags: [guidelines, screening-and-overdiagnosis] — cited by: guidelines.md, screening-and-overdiagnosis.md
• Jones S, et al. Clinical Impact and Accuracy of Shave Biopsy for Initial Diagnosis of Cutaneous Melanoma. The Journal of surgical research. 2023;286:35-40. PMID 36739830 — tags: [clinical-diagnosis-and-dermoscopy, histopathology-and-prognostic-factors, red-flags-and-safety-concerns] — cited by: clinical-diagnosis-and-dermoscopy.md, histopathology-and-prognostic-factors.md, red-flags-and-safety-concerns.md
• Kalkhoran S, et al. Historical, clinical, and dermoscopic characteristics of thin nodular melanoma. Archives of dermatology. 2010;146:311-8. PMID 20231503 — tags: [clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns] — cited by: clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md
• Kutzner H, et al. Overdiagnosis of melanoma - causes, consequences and solutions. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2020;18:1236-1243. PMID 32841508 — tags: [red-flags-and-safety-concerns, screening-and-overdiagnosis] — cited by: red-flags-and-safety-concerns.md, screening-and-overdiagnosis.md
• Lan J, et al. The diagnostic accuracy of dermoscopy and reflectance confocal microscopy for amelanotic/hypomelanotic melanoma: a systematic review and meta-analysis. The British journal of dermatology. 2020;183:210-219. PMID 31747045 — tags: [clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns] — cited by: clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md
• Lindsay D, et al. Cost-Effectiveness Analysis of 3D Total-Body Photography for People at High Risk of Melanoma. JAMA dermatology. 2025;161:482-489. PMID 40136266 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Liu W, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Archives of dermatology. 2006;142:1551-8. PMID 17178980 — tags: [clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns, special-populations] — cited by: clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md, special-populations.md
• López-Pardo Rico M, et al. Teledermatology vs. Face-to-Face Dermatology for the Diagnosis of Melanoma: A Systematic Review. Cancers. 2025;17. PMID 40940939 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• MacLellan AN, et al. The use of noninvasive imaging techniques in the diagnosis of melanoma: a prospective diagnostic accuracy study. Journal of the American Academy of Dermatology. 2021;85:353-359. PMID 32289389 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• McLoughlin KG, et al. A protocol for development of a microsimulation model platform to evaluate the potential benefits, harms, and cost-effectiveness of risk-tailored melanoma screening. PloS one. 2025;20:e0339177. PMID 41452872 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Mun JH, et al. Dermoscopy of subungual haemorrhage: its usefulness in differential diagnosis from nail-unit melanoma. The British journal of dermatology. 2013;168:1224-9. PMID 23302009 — tags: [clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns] — cited by: clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md
• Ng PC, et al. Evaluating invasive cutaneous melanoma: is the initial biopsy representative of the final depth?. Journal of the American Academy of Dermatology. 2003;48:420-4. PMID 12637923 — tags: [clinical-diagnosis-and-dermoscopy, histopathology-and-prognostic-factors] — cited by: clinical-diagnosis-and-dermoscopy.md, histopathology-and-prognostic-factors.md
• Olsen CM. Ecological evidence for melanoma overdiagnosis in Denmark. The British journal of dermatology. 2024;191:318-319. PMID 38752346 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Paiva ML, et al. Melanoma Overdiagnosis Is Not the Key Problem. JAMA dermatology. 2022;158:1082-1083. PMID 35895044 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Pellacani G, et al. Effect of Reflectance Confocal Microscopy for Suspect Lesions on Diagnostic Accuracy in Melanoma: A Randomized Clinical Trial. JAMA dermatology. 2022;158:754-761. PMID 35648432 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Piepkorn MW, et al. Assessment of Second-Opinion Strategies for Diagnoses of Cutaneous Melanocytic Lesions. JAMA network open. 2019;2:e1912597. PMID 31603483 — tags: [histopathology-and-prognostic-factors, red-flags-and-safety-concerns, screening-and-overdiagnosis] — cited by: histopathology-and-prognostic-factors.md, red-flags-and-safety-concerns.md, screening-and-overdiagnosis.md
• Rashid S, et al. Prognostic Implications of Primary Site in Cutaneous Head and Neck Melanoma After the Implementation of Sentinel Node Biopsy: A SEER-Based Analysis (2011-2020). Annals of surgical oncology. 2026;33:5002-5008. PMID 41803580 — tags: [brain-metastases, clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns, sentinel-node-and-nodal-management] — cited by: brain-metastases.md, clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md, sentinel-node-and-nodal-management.md
• Schreieder L, et al. Impact of Patient's Age and Physician's Professional Background on the Number Needed to Treat in Malignant Melanoma Detection. Cancers. 2024;16. PMID 39682200 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md
• Soltani-Arabshahi R, et al. Predictive value of biopsy specimens suspicious for melanoma: support for 6-mm criterion in the ABCD rule. Journal of the American Academy of Dermatology. 2015;72:412-8. PMID 25582536 — tags: [clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns] — cited by: clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md
• Soyer HP, et al. 3D Total-Body Photography in Patients at High Risk for Melanoma: A Randomized Clinical Trial. JAMA dermatology. 2025;161:472-481. PMID 40136310 — tags: [clinical-diagnosis-and-dermoscopy, screening-and-overdiagnosis] — cited by: clinical-diagnosis-and-dermoscopy.md, screening-and-overdiagnosis.md
• Vestergaard ME, et al. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. The British journal of dermatology. 2008;159:669-76. PMID 18616769 — tags: [clinical-diagnosis-and-dermoscopy, screening-and-overdiagnosis] — cited by: clinical-diagnosis-and-dermoscopy.md, screening-and-overdiagnosis.md
• Welch HG, et al. Overdiagnosis in cancer. Journal of the National Cancer Institute. 2010;102:605-13. PMID 20413742 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Welch HG, et al. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ (Clinical research ed.). 2005;331:481. PMID 16081427 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Wilson ECF, et al. A Modeling Study of the Cost-Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21:658-668. PMID 29909870 — tags: [screening-and-overdiagnosis] — cited by: screening-and-overdiagnosis.md
• Wu Q, et al. Clinicopathologic features, delayed diagnosis, and survival in amelanotic acral melanoma: A comparative study with pigmented melanoma. Journal of the American Academy of Dermatology. 2024;90:369-372. PMID 37690705 — tags: [acral-and-mucosal-melanoma, clinical-diagnosis-and-dermoscopy, red-flags-and-safety-concerns] — cited by: acral-and-mucosal-melanoma.md, clinical-diagnosis-and-dermoscopy.md, red-flags-and-safety-concerns.md
• Ye Z, et al. Deep learning algorithms for melanoma detection using dermoscopic images: A systematic review and meta-analysis. Artificial intelligence in medicine. 2024;155:102934. PMID 39088883 — tags: [clinical-diagnosis-and-dermoscopy] — cited by: clinical-diagnosis-and-dermoscopy.md

Pathology, staging and nodal management

• AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma. JAMA ophthalmology. 2015;133:376-83. PMID 25555246 — tags: [staging, uveal-melanoma] — cited by: staging.md, uveal-melanoma.md
• Bajaj S, et al. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition. Journal of the National Cancer Institute. 2020;112:921-928. PMID 31977051 — tags: [histopathology-and-prognostic-factors, staging] — cited by: histopathology-and-prognostic-factors.md, staging.md
• Balch CM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer. 1980;45:3012-7. PMID 7388745 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Cloyd JM, et al. Indocyanine green and fluorescence lymphangiography for sentinel lymph node identification in cutaneous melanoma. Journal of surgical oncology. 2014;110:888-92. PMID 25124992 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Cochran AJ, et al. Sentinel lymph node melanoma metastases: Assessment of tumor burden for clinical prediction of outcome in the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2022;48:1280-1287. PMID 35246348 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• de Vries M, et al. Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2005;31:778-83. PMID 15993029 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• de Vries M, et al. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2006;32:785-9. PMID 16806794 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• de Wet J, et al. Staged Excision of Lentigo Maligna of the Head and Neck: Assessing Surgical Excision Margins With Melan A, SOX10, and PRAME Immunohistochemistry. The American Journal of dermatopathology. 2023;45:107-112. PMID 36669074 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Dessinioti C, et al. Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. Journal of the National Cancer Institute. 2019;111:1314-1322. PMID 30863861 — tags: [histopathology-and-prognostic-factors, red-flags-and-safety-concerns] — cited by: histopathology-and-prognostic-factors.md, red-flags-and-safety-concerns.md
• Elder DE, et al. The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway. Archives of pathology & laboratory medicine. 2020;144:500-522. PMID 32057276 — tags: [histopathology-and-prognostic-factors, molecular-subtypes-and-genomics] — cited by: histopathology-and-prognostic-factors.md, molecular-subtypes-and-genomics.md
• Fujisawa Y, et al. Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system. Journal of dermatological science. 2019;94:284-289. PMID 31023613 — tags: [staging] — cited by: staging.md
• Gambichler T, et al. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. European journal of cancer (Oxford, England : 1990). 2021;143:11-18. PMID 33278769 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Gaudy-Marqueste C, et al. Initial metastatic kinetics is the best prognostic indicator in stage IV metastatic melanoma. European journal of cancer (Oxford, England : 1990). 2014;50:1120-4. PMID 24440089 — tags: [immunotherapy-advanced-disease, staging] — cited by: immunotherapy-advanced-disease.md, staging.md
• Gershenwald JE, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017;67:472-492. PMID 29028110 — tags: [brain-metastases, guidelines, histopathology-and-prognostic-factors, sentinel-node-and-nodal-management, staging, surgical-management-and-margins] — cited by: brain-metastases.md, guidelines.md, histopathology-and-prognostic-factors.md, sentinel-node-and-nodal-management.md, staging.md, surgical-management-and-margins.md
• Gjorup CA, et al. Factors associated with melanoma-related limb lymphoedema. Acta oncologica (Stockholm, Sweden). 2021;60:779-784. PMID 33793386 — tags: [sentinel-node-and-nodal-management, surveillance-and-survivorship] — cited by: sentinel-node-and-nodal-management.md, surveillance-and-survivorship.md
• Gradecki SE, et al. PRAME immunohistochemistry as an adjunct for diagnosis and histological margin assessment in lentigo maligna. Histopathology. 2021;78:1000-1008. PMID 33280156 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Grande Sarpa H, et al. Prognostic significance of extent of ulceration in primary cutaneous melanoma. The American journal of surgical pathology. 2006;30:1396-400. PMID 17063079 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Grover P, et al. Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2025;36:807-818. PMID 40204154 — tags: [adjuvant-therapy, guidelines, staging] — cited by: adjuvant-therapy.md, guidelines.md, staging.md
• Gualano MR, et al. Prognostic role of histological regression in primary cutaneous melanoma: a systematic review and meta-analysis. The British journal of dermatology. 2018;178:357-362. PMID 28386936 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Hanks JE, et al. Sentinel Lymph Node Biopsy in Head and Neck Melanoma: Long-term Outcomes, Prognostic Value, Accuracy, and Safety. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2020;162:520-529. PMID 32041486 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Huang H, et al. Predictive Values of Pathological and Clinical Risk Factors for Positivity of Sentinel Lymph Node Biopsy in Thin Melanoma: A Systematic Review and Meta-Analysis. Frontiers in oncology. 2022;12:817510. PMID 35155254 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Hynes MC, et al. A population-based validation study of the 8th edition UICC/AJCC TNM staging system for cutaneous melanoma. BMC cancer. 2022;22:720. PMID 35778691 — tags: [staging] — cited by: staging.md
• Isaksson K, et al. A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. Annals of surgical oncology. 2019;26:2839-2845. PMID 31111349 — tags: [staging] — cited by: staging.md
• Janka EA, et al. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1. Frontiers in oncology. 2023;13:1237643. PMID 37664072 — tags: [brain-metastases, immunotherapy-advanced-disease, staging] — cited by: brain-metastases.md, immunotherapy-advanced-disease.md, staging.md
• Kaczorowski M, et al. PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors. The American journal of surgical pathology. 2022;46:1467-1476. PMID 35973038 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Knackstedt RW, et al. Indocyanine green fluorescence imaging with lymphoscintigraphy for sentinel node biopsy in head and neck melanoma. The Journal of surgical research. 2018;228:77-83. PMID 29907233 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Knezevich SR, et al. Variability in mitotic figures in serial sections of thin melanomas. Journal of the American Academy of Dermatology. 2014;71:1204-11. PMID 25239732 — tags: [histopathology-and-prognostic-factors, staging] — cited by: histopathology-and-prognostic-factors.md, staging.md
• Lallas K, et al. Clinical, dermatoscopic, histological and molecular predictive factors of distant melanoma metastasis: A systematic review and meta-analysis. Critical reviews in oncology/hematology. 2024;202:104458. PMID 39074631 — tags: [staging] — cited by: staging.md
• Lavy D, et al. ICG-guided sentinel lymph node biopsy in melanoma is as effective as blue dye: A retrospective analysis. Surgical oncology. 2024;57:102167. PMID 39581000 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Lorimer PD, et al. Reporting of mitotic rate in cutaneous melanoma: A study using the national cancer data base. Journal of surgical oncology. 2017;115:281-286. PMID 28335082 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Mandalà M, et al. Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study. ESMO open. 2022;7:100469. PMID 35421840 — tags: [acral-and-mucosal-melanoma, histopathology-and-prognostic-factors, red-flags-and-safety-concerns, staging] — cited by: acral-and-mucosal-melanoma.md, histopathology-and-prognostic-factors.md, red-flags-and-safety-concerns.md, staging.md
• Maurichi A, et al. Factors Affecting Sentinel Node Metastasis in Thin (T1) Cutaneous Melanomas: Development and External Validation of a Predictive Nomogram. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020;38:1591-1601. PMID 32167862 — tags: [histopathology-and-prognostic-factors, sentinel-node-and-nodal-management, staging] — cited by: histopathology-and-prognostic-factors.md, sentinel-node-and-nodal-management.md, staging.md
• May CJ, et al. Factors associated with use of immunohistochemical markers in the histopathological diagnosis of cutaneous melanocytic lesions. Journal of cutaneous pathology. 2020;47:896-902. PMID 32383301 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• McCahill LE, et al. Missed Opportunities for Neoadjuvant Immunotherapy in Melanoma: Is it Time to Consider Ultrasound Staging for Newly Diagnosed Patients?. Annals of surgical oncology. 2026;. PMID 42581274 — tags: [staging] — cited by: staging.md
• Mentzel T. [Immunohistochemistry of melanocytic tumours]. Pathologie (Heidelberg, Germany). 2026;. PMID 41790207 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Michel J, et al. Sinonasal mucosal melanomas: the prognostic value of tumor classifications. Head & neck. 2014;36:311-6. PMID 23729399 — tags: [acral-and-mucosal-melanoma, guidelines, staging] — cited by: acral-and-mucosal-melanoma.md, guidelines.md, staging.md
• Mijnhout GS, et al. Systematic review of the diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography in melanoma patients. Cancer. 2001;91:1530-42. PMID 11301402 — tags: [staging] — cited by: staging.md
• Morton DL, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. The New England journal of medicine. 2014;370:599-609. PMID 24521106 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Moya-Plana A, et al. Risk-based stratification in head and neck mucosal melanoma. Oral oncology. 2019;97:44-49. PMID 31421470 — tags: [acral-and-mucosal-melanoma, guidelines, staging] — cited by: acral-and-mucosal-melanoma.md, guidelines.md, staging.md
• Namikawa K, et al. Clinical impact of ulceration width, lymphovascular invasion, microscopic satellitosis, perineural invasion, and mitotic rate in patients undergoing sentinel lymph node biopsy for cutaneous melanoma: a retrospective observational study at a comprehensive cancer center. Cancer medicine. 2018;7:583-593. PMID 29464914 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Namikawa K, et al. Sentinel lymph node biopsy guided by indocyanine green fluorescence for cutaneous melanoma. European journal of dermatology : EJD. 2011;21:184-90. PMID 21498148 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Nicolson NG, et al. Desmoplastic melanoma. Journal of surgical oncology. 2019;119:208-215. PMID 30481377 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• O'Hern K, et al. Intraoperative Immunohistochemistry During Mohs Micrographic Surgery and Staged Excision Decreases Local Recurrence Rates for Invasive Cutaneous Melanoma: A Systematic Review and Meta-Analysis. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2024;50:601-610. PMID 38530980 — tags: [histopathology-and-prognostic-factors, surgical-management-and-margins] — cited by: histopathology-and-prognostic-factors.md, surgical-management-and-margins.md
• Pasha T, et al. Association of Complex Lymphatic Drainage in Head and Neck Cutaneous Melanoma With Sentinel Lymph Node Biopsy Outcomes: A Cohort Study and Literature Review. JAMA otolaryngology-- head & neck surgery. 2023;149:416-423. PMID 36892824 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Paver EC, et al. Prognostic Significance of Incipient Ulceration in Primary Cutaneous Melanoma. JAMA dermatology. 2023;159:1359-1367. PMID 37910123 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Rosenthal A, et al. Tumor upstaging in invasive melanoma is associated with changes in clinical management and worse prognosis. Journal of the American Academy of Dermatology. 2025;92:528-537. PMID 39579989 — tags: [staging] — cited by: staging.md
• Roshan A, et al. [(99m)Tc]Tc-Tilmanocept sentinel node biopsy and long-term outcomes in melanoma: A cohort study and literature review. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2026;52:112065. PMID 42617582 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Saad M, et al. Performance of preferentially expressed antigen in melanoma (PRAME) immunohistochemistry for metastatic melanoma in cytology specimens. Diagnostic cytopathology. 2024;52:362-368. PMID 38558495 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Saleem A, et al. Immunohistochemistry in melanocytic lesions: Updates with a practical review for pathologists. Seminars in diagnostic pathology. 2022;39:239-247. PMID 35016807 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Sars C, et al. Risk Factors for Complications and Long-Term Outcomes Following Completion Lymph Node Dissection for Cutaneous Melanoma: A Retrospective Cohort Study. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2020;73:1540-1546. PMID 32467082 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Satzger I, et al. Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden. European journal of cancer (Oxford, England : 1990). 2019;123:83-91. PMID 31677550 — tags: [histopathology-and-prognostic-factors, sentinel-node-and-nodal-management, staging] — cited by: histopathology-and-prognostic-factors.md, sentinel-node-and-nodal-management.md, staging.md
• Schuiveling M, et al. Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma. JAMA oncology. 2025;11:1470-1478. PMID 41100131 — tags: [histopathology-and-prognostic-factors, immunotherapy-advanced-disease] — cited by: histopathology-and-prognostic-factors.md, immunotherapy-advanced-disease.md
• Senders ZJ, et al. Does Stage Migration Occur as a Consequence of Omitting Completion Lymph Node Dissection for Melanoma?. Annals of surgical oncology. 2023;30:3648-3654. PMID 36934378 — tags: [staging] — cited by: staging.md
• Shen C, et al. Lymphadenectomy After Melanoma-A National Analysis of Recurrence Rates and Risk of Lymphedema. Annals of plastic surgery. 2024;92:S284-S292. PMID 38556691 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Spillane AJ, et al. Lymph node ratio provides prognostic information in addition to american joint committee on cancer N stage in patients with melanoma, even if quality of surgery is standardized. Annals of surgery. 2011;253:109-15. PMID 21119509 — tags: [histopathology-and-prognostic-factors, sentinel-node-and-nodal-management, staging] — cited by: histopathology-and-prognostic-factors.md, sentinel-node-and-nodal-management.md, staging.md
• Straker RJ 3rd, et al. Prognostic Significance of Primary Tumor-Infiltrating Lymphocytes in a Contemporary Melanoma Cohort. Annals of surgical oncology. 2022;29:5207-5216. PMID 35301610 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Stålhammar G, et al. Improved Staging of Ciliary Body and Choroidal Melanomas Based on Estimation of Tumor Volume and Competing Risk Analyses. Ophthalmology. 2024;131:478-491. PMID 38071620 — tags: [staging, uveal-melanoma] — cited by: staging.md, uveal-melanoma.md
• Sun Q, et al. Prognostic Significance of Tumor-Infiltrating Lymphocyte Grade in Melanoma: A Meta-Analysis. Dermatology (Basel, Switzerland). 2020;236:481-492. PMID 32023619 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Thomas JM. Concerns relating to the conduct and statistical analysis of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in patients with melanoma. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2009;62:442-6. PMID 19246272 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Tjokrowidjaja A, et al. External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program. Asia-Pacific journal of clinical oncology. 2022;18:e280-e288. PMID 34811927 — tags: [staging] — cited by: staging.md
• van den Berg NS, et al. Multimodal Surgical Guidance during Sentinel Node Biopsy for Melanoma: Combined Gamma Tracing and Fluorescence Imaging of the Sentinel Node through Use of the Hybrid Tracer Indocyanine Green-(99m)Tc-Nanocolloid. Radiology. 2015;275:521-9. PMID 25521776 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Verver D, et al. The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection. European journal of cancer (Oxford, England : 1990). 2020;134:9-18. PMID 32454396 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Voiculescu VM, et al. Immunohistochemistry for Skin Cancers: New Insights into Diagnosis and Treatment of Melanoma. Cancers. 2025;17. PMID 40507250 — tags: [histopathology-and-prognostic-factors] — cited by: histopathology-and-prognostic-factors.md
• Walker RJB, et al. Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma: An International Multi-institutional Collaboration. Annals of surgical oncology. 2022;29:7010-7017. PMID 35676603 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Warycha MA, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer. 2009;115:869-79. PMID 19117354 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Weitemeyer MB, et al. More sentinel lymph node biopsies for thin melanomas after transition to AJCC 8th edition do not increase positivity rate: A Danish population-based study of 7148 patients. Journal of surgical oncology. 2022;125:498-508. PMID 34672372 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md
• Yee P, et al. Sentinel Lymph Node Biopsy for Desmoplastic Melanoma: A Systematic Review and Meta-analysis. Annals of surgical oncology. 2026;33:6719-6727. PMID 41870859 — tags: [histopathology-and-prognostic-factors, sentinel-node-and-nodal-management, staging] — cited by: histopathology-and-prognostic-factors.md, sentinel-node-and-nodal-management.md, staging.md
• Zager JS, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC cancer. 2018;18:130. PMID 29402264 — tags: [histopathology-and-prognostic-factors, molecular-subtypes-and-genomics, sentinel-node-and-nodal-management, staging] — cited by: histopathology-and-prognostic-factors.md, molecular-subtypes-and-genomics.md, sentinel-node-and-nodal-management.md, staging.md
• Zaremba A, et al. Genetic and methylation profiles distinguish benign, malignant and spitzoid melanocytic tumors. International journal of cancer. 2022;151:1542-1554. PMID 35737508 — tags: [histopathology-and-prognostic-factors, molecular-subtypes-and-genomics, special-populations] — cited by: histopathology-and-prognostic-factors.md, molecular-subtypes-and-genomics.md, special-populations.md
• Zhang Y, et al. Sentinel lymph node detection in melanoma: indocyanine green fluorescence compared with conventional mapping techniques. Melanoma research. 2026;36:339-343. PMID 42108206 — tags: [sentinel-node-and-nodal-management] — cited by: sentinel-node-and-nodal-management.md

Molecular biology and genomics

• Yamamoto M, et al. The 31-gene expression profile test informs sentinel lymph node biopsy decisions in patients with cutaneous melanoma: results of a prospective, multicenter study. Current medical research and opinion. 2023;39:417-423. PMID 36617959 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md

• Guenther JM, et al. A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma. World journal of surgical oncology. 2025;23:5. PMID 39754143 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md

• Alexandrov LB, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415-21. PMID 23945592 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md

• Alexandrov LB, et al. The repertoire of mutational signatures in human cancer. Nature. 2020;578:94-101. PMID 32025018 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md
• Ayers M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. The Journal of clinical investigation. 2017;127:2930-2940. PMID 28650338 — tags: [immunotherapy-advanced-disease, molecular-subtypes-and-genomics] — cited by: immunotherapy-advanced-disease.md, molecular-subtypes-and-genomics.md
• Bowman RL, et al. UVB mutagenesis differs in Nras- and Braf-mutant mouse models of melanoma. Life science alliance. 2021;4. PMID 34210801 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md
• Cabrita R, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577:561-565. PMID 31942071 — tags: [cellular-therapy-and-resistance, immunotherapy-advanced-disease, molecular-subtypes-and-genomics] — cited by: cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md, molecular-subtypes-and-genomics.md
• Chang GA, et al. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors. The Journal of investigative dermatology. 2020;140:1609-1618.e7. PMID 32087194 — tags: [cellular-therapy-and-resistance, molecular-subtypes-and-genomics] — cited by: cellular-therapy-and-resistance.md, molecular-subtypes-and-genomics.md
• Gong HZ, et al. The clinical significance of KIT mutations in melanoma: a meta-analysis. Melanoma research. 2018;28:259-270. PMID 29746316 — tags: [acral-and-mucosal-melanoma, molecular-subtypes-and-genomics, special-populations, targeted-therapy] — cited by: acral-and-mucosal-melanoma.md, molecular-subtypes-and-genomics.md, special-populations.md, targeted-therapy.md
• Grasso CS, et al. Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma. Cancer cell. 2020;38:500-515.e3. PMID 32916126 — tags: [cellular-therapy-and-resistance, immunotherapy-advanced-disease, molecular-subtypes-and-genomics] — cited by: cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md, molecular-subtypes-and-genomics.md
• Heppt MV, et al. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care. BMC cancer. 2017;17:536. PMID 28797232 — tags: [molecular-subtypes-and-genomics, targeted-therapy] — cited by: molecular-subtypes-and-genomics.md, targeted-therapy.md
• Horn S, et al. TERT promoter mutations in familial and sporadic melanoma. Science (New York, N.Y.). 2013;339:959-61. PMID 23348503 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md
• Hsueh EC, et al. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. Journal of hematology & oncology. 2017;10:152. PMID 28851416 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md
• Keller J, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. Cancer medicine. 2019;8:2205-2212. PMID 30950242 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md
• Lim SY, et al. The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nature communications. 2023;14:1516. PMID 36934113 — tags: [brain-metastases, cellular-therapy-and-resistance, immunotherapy-advanced-disease, molecular-subtypes-and-genomics] — cited by: brain-metastases.md, cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md, molecular-subtypes-and-genomics.md
• Peng W, et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer discovery. 2016;6:202-16. PMID 26645196 — tags: [cellular-therapy-and-resistance, molecular-subtypes-and-genomics] — cited by: cellular-therapy-and-resistance.md, molecular-subtypes-and-genomics.md
• Rizos H, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014;20:1965-77. PMID 24463458 — tags: [cellular-therapy-and-resistance, molecular-subtypes-and-genomics, targeted-therapy] — cited by: cellular-therapy-and-resistance.md, molecular-subtypes-and-genomics.md, targeted-therapy.md
• Shain AH, et al. Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution. Cancer cell. 2018;34:45-55.e4. PMID 29990500 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md
• Tirosh I, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, N.Y.). 2016;352:189-96. PMID 27124452 — tags: [cellular-therapy-and-resistance, molecular-subtypes-and-genomics, targeted-therapy] — cited by: cellular-therapy-and-resistance.md, molecular-subtypes-and-genomics.md, targeted-therapy.md
• Vergara IA, et al. Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. Nature communications. 2021;12:1434. PMID 33664264 — tags: [molecular-subtypes-and-genomics] — cited by: molecular-subtypes-and-genomics.md
• Zaretsky JM, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. The New England journal of medicine. 2016;375:819-29. PMID 27433843 — tags: [cellular-therapy-and-resistance, molecular-subtypes-and-genomics] — cited by: cellular-therapy-and-resistance.md, molecular-subtypes-and-genomics.md

Surgery and locoregional therapy

• Adalsteinsson JA, et al. Limitations in the literature regarding Mohs surgery and staged excision for melanoma: A critical review of quality and data reporting. Journal of the American Academy of Dermatology. 2023;88:404-413. PMID 33872715 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Andtbacka RHI, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. Journal for immunotherapy of cancer. 2019;7:145. PMID 31171039 — tags: [cellular-therapy-and-resistance, surgical-management-and-margins] — cited by: cellular-therapy-and-resistance.md, surgical-management-and-margins.md
• Bittar PG, et al. Systematic review and meta-analysis of local recurrence rates of head and neck cutaneous melanomas after wide local excision, Mohs micrographic surgery, or staged excision. Journal of the American Academy of Dermatology. 2021;85:681-692. PMID 33961921 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Deboever N, et al. The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. The Journal of surgical research. 2022;277:125-130. PMID 35489217 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Dessinioti C, et al. Local recurrence of non-lentigo maligna melanoma in situ and safety excision margins: A systematic review. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2025;23:805-812. PMID 40231559 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Dugan MM, et al. Isolated Limb Infusion/Perfusion for Unresectable Acral Versus Non-Acral Melanoma In-Transit Metastases. Annals of surgical oncology. 2025;32:6920-6926. PMID 40413325 — tags: [acral-and-mucosal-melanoma, surgical-management-and-margins] — cited by: acral-and-mucosal-melanoma.md, surgical-management-and-margins.md
• Faries MB. Melanoma trials that defined surgical management. Journal of surgical oncology. 2022;125:34-37. PMID 34897707 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Floriano LS, et al. Surgical Excision Margins in Skin Melanomas with Breslow Thickness Greater than 2 mm: A Systematic Review and Meta-Analysis. Current pharmaceutical design. 2026;32:301-305. PMID 40108923 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Garbe C, et al. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024. European journal of cancer (Oxford, England : 1990). 2025;215:115153. PMID 39709737 — tags: [adjuvant-therapy, guidelines, neoadjuvant-therapy, surgical-management-and-margins] — cited by: adjuvant-therapy.md, guidelines.md, neoadjuvant-therapy.md, surgical-management-and-margins.md
• Gillgren P, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet (London, England). 2011;378:1635-42. PMID 22027547 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Hayes AJ, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. The Lancet. Oncology. 2016;17:184-192. PMID 26790922 — tags: [acral-and-mucosal-melanoma, surgical-management-and-margins] — cited by: acral-and-mucosal-melanoma.md, surgical-management-and-margins.md
• Howard JH, et al. Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Annals of surgical oncology. 2012;19:2547-55. PMID 22648554 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Krausz AE, et al. Systematic Review of Technical Variations for Mohs Micrographic Surgery for Melanoma. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2021;47:1539-1544. PMID 34743123 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Levoska MA, et al. Upstaging of melanoma in situ and lentigo maligna treated with Mohs micrographic surgery rarely results in additional surgical management. Archives of dermatological research. 2020;312:753-756. PMID 32002653 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Matteucci M, et al. Rethinking Lymphadenectomy in Cutaneous Melanoma: From Routine Practice to Selective Indication: A Narrative Review. Medicina (Kaunas, Lithuania). 2025;61. PMID 41011113 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Mocellin S, et al. The impact of surgery on survival of patients with cutaneous melanoma: revisiting the role of primary tumor excision margins. Annals of surgery. 2011;253:238-43. PMID 21173691 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Moncrieff MD, et al. 1 Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study. Annals of surgical oncology. 2018;25:2541-2549. PMID 29850955 — tags: [clinical-trials-landscape, patient-experience-and-advocacy, surgical-management-and-margins] — cited by: clinical-trials-landscape.md, patient-experience-and-advocacy.md, surgical-management-and-margins.md
• Nelson DW, et al. Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis. Annals of surgical oncology. 2019;26:4610-4618. PMID 31183639 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Pharis DB. Cutaneous melanoma: therapeutic lymph node and elective lymph node dissections, lymphatic mapping, and sentinel lymph node biopsy. Dermatologic therapy. 2005;18:397-406. PMID 16297015 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Piepkorn M, et al. Theoretical and empirical arguments in relation to elective lymph node dissection for melanoma. Archives of dermatology. 1997;133:995-1002. PMID 9267247 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Plitas G, et al. Controversies in the management of regional nodes in melanoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2012;10:414-21. PMID 22393199 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Read T, et al. A systematic review and meta-analysis of locoregional treatments for in-transit melanoma. Journal of surgical oncology. 2019;119:887-896. PMID 30734295 — tags: [cellular-therapy-and-resistance, surgical-management-and-margins] — cited by: cellular-therapy-and-resistance.md, surgical-management-and-margins.md
• Reijers ILM, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nature medicine. 2022;28:1178-1188. PMID 35661157 — tags: [clinical-trials-landscape, neoadjuvant-therapy, surgical-management-and-margins] — cited by: clinical-trials-landscape.md, neoadjuvant-therapy.md, surgical-management-and-margins.md
• Sladden MJ, et al. Surgical excision margins for primary cutaneous melanoma. The Cochrane database of systematic reviews. 2009;:CD004835. PMID 19821334 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Swetter SM, et al. Guidelines of care for the management of primary cutaneous melanoma. Journal of the American Academy of Dermatology. 2019;80:208-250. PMID 30392755 — tags: [guidelines, surgical-management-and-margins] — cited by: guidelines.md, surgical-management-and-margins.md
• Tate JA, et al. Excision margins for melanoma in situ on the head and neck-A single-center 10-year retrospective review of treatment with Mohs micrographic surgery. Journal of the American Academy of Dermatology. 2024;90:1226-1231. PMID 38253130 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Tzellos T, et al. Interventions for melanoma in situ, including lentigo maligna. The Cochrane database of systematic reviews. 2014;2014:CD010308. PMID 25526608 — tags: [surgical-management-and-margins] — cited by: surgical-management-and-margins.md
• Wright FC, et al. Locoregional management of in-transit metastasis in melanoma: an Ontario Health (Cancer Care Ontario) clinical practice guideline. Current oncology (Toronto, Ont.). 2020;27:e318-e325. PMID 32669939 — tags: [guidelines, surgical-management-and-margins] — cited by: guidelines.md, surgical-management-and-margins.md

Adjuvant and neoadjuvant systemic therapy

• Gorry C, et al. Neoadjuvant treatment for stage III and IV cutaneous melanoma. The Cochrane database of systematic reviews. 2023;1:CD012974. PMID 36648215 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md

• Lucas MW, et al. Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity. Immunity. 2026;59:29-33.e2. PMID 41478279 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md

• Amaria RN, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022;611:155-160. PMID 36289334 — tags: [clinical-trials-landscape, immune-related-adverse-events, neoadjuvant-therapy] — cited by: clinical-trials-landscape.md, immune-related-adverse-events.md, neoadjuvant-therapy.md

• Andreikos DA, et al. Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma. Targeted oncology. 2026;21:421-432. PMID 42101794 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Berciano-Guerrero MÁ, et al. Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study. Cancer. 2026;132:e70497. PMID 42411543 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Burmeister BH, et al. A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma-Trans Tasman Radiation Oncology Group (TROG) Study 96.06. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2006;81:136-42. PMID 17064803 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Burton EM, et al. Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025;43:2856-2862. PMID 40638872 — tags: [clinical-trials-landscape, neoadjuvant-therapy] — cited by: clinical-trials-landscape.md, neoadjuvant-therapy.md
• Bührer E, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet. Oncology. 2024;25:1202-1212. PMID 39146951 — tags: [adjuvant-therapy, patient-experience-and-advocacy] — cited by: adjuvant-therapy.md, patient-experience-and-advocacy.md
• Coens C, et al. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2017;18:393-403. PMID 28162999 — tags: [adjuvant-therapy, patient-experience-and-advocacy] — cited by: adjuvant-therapy.md, patient-experience-and-advocacy.md
• Conill C, et al. Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2009;11:688-93. PMID 19828412 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Cronin C, et al. Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland. The oncologist. 2025;30. PMID 40857557 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Deutsch JS, et al. Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effort. Annals of oncology : official journal of the European Society for Medical Oncology. 2026;37:141-154. PMID 41469296 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Dougherty KE, et al. Implementing Paradigm Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients. Annals of surgical oncology. 2026;33:7952-7959. PMID 42360644 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Eggermont AM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. The Lancet. Oncology. 2015;16:522-30. PMID 25840693 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Eggermont AMM, et al. Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. European journal of cancer (Oxford, England : 1990). 2019;119:1-10. PMID 31400634 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Eljilany I, et al. Estimated cost-effectiveness of adjuvant nivolumab for resected stage IIB-IIC melanoma in the United States. Expert review of pharmacoeconomics & outcomes research. 2026;26:667-681. PMID 42033368 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Hennequin C, et al. Radiation therapy of cutaneous cancers. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2022;26:397-403. PMID 34955421 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Kirkwood JM. Response to letter to the editor on "Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76K trial". European journal of cancer (Oxford, England : 1990). 2025;227:115636. PMID 40680468 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Kuijpers AMJ, et al. Neo-Adjuvant Therapy for Metastatic Melanoma. Cancers. 2024;16. PMID 38610925 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Larkin J, et al. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. European journal of cancer (Oxford, England : 1990). 2022;173:285-296. PMID 35964471 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Larkin J, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023;29:3352-3361. PMID 37058595 — tags: [adjuvant-therapy, immunotherapy-advanced-disease] — cited by: adjuvant-therapy.md, immunotherapy-advanced-disease.md
• Leachman SA, et al. Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open. 2026;9:e2559603. PMID 41701495 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Long GV, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. The New England journal of medicine. 2017;377:1813-1823. PMID 28891408 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Long GV, et al. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. The New England journal of medicine. 2024;391:1709-1720. PMID 38899716 — tags: [adjuvant-therapy, targeted-therapy] — cited by: adjuvant-therapy.md, targeted-therapy.md
• Long GV, et al. Neoadjuvant Checkpoint Immunotherapy and Melanoma: The Time Is Now. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41:3236-3248. PMID 37104746 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Long GV, et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF(V600) mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. The Lancet. Oncology. 2019;20:961-971. PMID 31171444 — tags: [clinical-trials-landscape, neoadjuvant-therapy] — cited by: clinical-trials-landscape.md, neoadjuvant-therapy.md
• Long GV, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. The Lancet. Oncology. 2022;23:1378-1388. PMID 36265502 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Luke JJ, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet (London, England). 2022;399:1718-1729. PMID 35367007 — tags: [adjuvant-therapy, clinical-trials-landscape, special-populations] — cited by: adjuvant-therapy.md, clinical-trials-landscape.md, special-populations.md
• Luke JJ, et al. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024;42:1619-1624. PMID 38452313 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Menzies AM, et al. Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2024;35:739-746. PMID 38754780 — tags: [clinical-trials-landscape, neoadjuvant-therapy, targeted-therapy] — cited by: clinical-trials-landscape.md, neoadjuvant-therapy.md, targeted-therapy.md
• Papadopoulos N, et al. Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma. Cancers. 2026;18. PMID 42352510 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Patel SP, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine. 2023;388:813-823. PMID 36856617 — tags: [adjuvant-therapy, clinical-trials-landscape, guidelines, immune-related-adverse-events, neoadjuvant-therapy] — cited by: adjuvant-therapy.md, clinical-trials-landscape.md, guidelines.md, immune-related-adverse-events.md, neoadjuvant-therapy.md
• Reddish S, et al. Neoadjuvant systemic therapy in stage III and IV resectable melanoma: an update to management and future directions. The New Zealand medical journal. 2026;139:93-99. PMID 41990381 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Rozeman EA, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. The Lancet. Oncology. 2019;20:948-960. PMID 31160251 — tags: [clinical-trials-landscape, immune-related-adverse-events, neoadjuvant-therapy] — cited by: clinical-trials-landscape.md, immune-related-adverse-events.md, neoadjuvant-therapy.md
• Rozeman EA, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nature medicine. 2021;27:256-263. PMID 33558721 — tags: [clinical-trials-landscape, immunotherapy-advanced-disease, neoadjuvant-therapy] — cited by: clinical-trials-landscape.md, immunotherapy-advanced-disease.md, neoadjuvant-therapy.md
• Schadendorf D, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for immunotherapy of cancer. 2024;12. PMID 38485189 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Seth R, et al. Systemic Therapy for Melanoma: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41:4794-4820. PMID 37579248 — tags: [guidelines, neoadjuvant-therapy] — cited by: guidelines.md, neoadjuvant-therapy.md
• Staeger R, et al. Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland. Cancers. 2024;16. PMID 38473216 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Suciu S, et al. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. Journal of the National Cancer Institute. 2018;110. PMID 28922786 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Syeda MM, et al. Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial. The Lancet. Oncology. 2025;26:641-653. PMID 40250457 — tags: [adjuvant-therapy, surveillance-and-survivorship] — cited by: adjuvant-therapy.md, surveillance-and-survivorship.md
• Tetzlaff MT, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2018;29:1861-1868. PMID 29945191 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Tomsitz D, et al. Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma. Journal of the European Academy of Dermatology and Venereology : JEADV. 2025;39:1975-1986. PMID 40119686 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• van Akkooi ACJ, et al. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. European journal of cancer (Oxford, England : 1990). 2023;182:38-42. PMID 36738540 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Versluis JM, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Annals of oncology : official journal of the European Society for Medical Oncology. 2023;34:420-430. PMID 36681299 — tags: [neoadjuvant-therapy] — cited by: neoadjuvant-therapy.md
• Weber J, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. The New England journal of medicine. 2017;377:1824-1835. PMID 28891423 — tags: [adjuvant-therapy, immune-related-adverse-events] — cited by: adjuvant-therapy.md, immune-related-adverse-events.md
• Weber J, et al. Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024;42:3702-3712. PMID 39102624 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Weber JS, et al. Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025;43:929-937. PMID 39378385 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Yoon CH, et al. Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial. Annals of surgical oncology. 2025;32:2756-2764. PMID 39893343 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Zhang S, et al. Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States. Advances in therapy. 2023;40:3038-3055. PMID 37191852 — tags: [adjuvant-therapy] — cited by: adjuvant-therapy.md
• Özkan A, et al. Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry. European journal of cancer (Oxford, England : 1990). 2024;212:115056. PMID 39368226 — tags: [adjuvant-therapy, immune-related-adverse-events, red-flags-and-safety-concerns, special-populations] — cited by: adjuvant-therapy.md, immune-related-adverse-events.md, red-flags-and-safety-concerns.md, special-populations.md

Systemic therapy for advanced disease

• Abdulhaleem M, et al. Patterns of Failure Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Melanoma Brain Metastases. Neurosurgery practice. 2023;4:e00026. PMID 39959719 — tags: [brain-metastases] — cited by: brain-metastases.md
• Albert NL, et al. RANO criteria for response assessment of brain metastases based on amino acid PET imaging. Nature medicine. 2025;31:1424-1430. PMID 40341837 — tags: [brain-metastases] — cited by: brain-metastases.md
• Amaral T, et al. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. European journal of cancer (Oxford, England : 1990). 2017;73:93-101. PMID 28162869 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Ascierto PA, et al. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF(V600) mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study. The Lancet. Oncology. 2023;24:33-44. PMID 36460017 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Atkinson V, et al. Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. European journal of cancer (Oxford, England : 1990). 2022;163:79-87. PMID 35042070 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Awidi M, et al. Safety of sequential immune checkpoint inhibitors after prior immune therapy. Journal of cancer research and clinical oncology. 2023;149:2375-2382. PMID 35727369 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Badrigilan S, et al. Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study. British journal of neurosurgery. 2023;37:1533-1543. PMID 34979828 — tags: [brain-metastases] — cited by: brain-metastases.md
• Bartula I, et al. Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial. Clinical and translational radiation oncology. 2023;41:100597. PMID 37441544 — tags: [brain-metastases] — cited by: brain-metastases.md
• Berz AM, et al. Tumor response assessment on imaging following immunotherapy. Frontiers in oncology. 2022;12:982983. PMID 36387133 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Borcoman E, et al. Patterns of Response and Progression to Immunotherapy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. 2018;38:169-178. PMID 30231380 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Broderick JC, et al. Melanoma Vaccines: Comparing Novel Adjuvant Treatments in High-Risk Patients. Vaccines. 2025;13. PMID 40573987 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Brower JV, et al. Management of leptomeningeal metastases: Prognostic factors and associated outcomes. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. 2016;27:130-7. PMID 26778048 — tags: [brain-metastases] — cited by: brain-metastases.md
• Cai C, et al. Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma. JAMA network open. 2021;4:e2132262. PMID 34762112 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Cao J, et al. Efficacy and safety of immune checkpoint inhibitors rechallenge in advanced solid tumors: a systematic review and meta-analysis. Frontiers in oncology. 2024;14:1475502. PMID 39726701 — tags: [cellular-therapy-and-resistance, immunotherapy-advanced-disease] — cited by: cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md
• Chapman PB, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2017;28:2581-2587. PMID 28961848 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Chesney J, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. Journal for immunotherapy of cancer. 2022;10. PMID 36600653 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Cosci I, et al. Molecular Basis of BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Pharmaceuticals (Basel, Switzerland). 2025;18. PMID 40872623 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• da Silva IP, et al. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. ESMO open. 2025;10:105833. PMID 41202502 — tags: [cellular-therapy-and-resistance, immunotherapy-advanced-disease] — cited by: cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md
• Daud A, et al. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma. The oncologist. 2017;22:823-833. PMID 28526719 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Davar D, et al. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. Journal for immunotherapy of cancer. 2017;5:74. PMID 28923120 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Davies MA, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. The Lancet. Oncology. 2017;18:863-873. PMID 28592387 — tags: [brain-metastases] — cited by: brain-metastases.md
• Douri K, et al. Response Assessment in Brain Metastases Managed by Stereotactic Radiosurgery: A Reappraisal of the RANO-BM Criteria. Current oncology (Toronto, Ont.). 2023;30:9382-9391. PMID 37999099 — tags: [brain-metastases] — cited by: brain-metastases.md
• Dummer R, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology. 2018;19:603-615. PMID 29573941 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Dummer R, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. 2018;19:1315-1327. PMID 30219628 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Gabani P, et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2018;128:266-273. PMID 29960685 — tags: [brain-metastases] — cited by: brain-metastases.md
• Geukes Foppen MH, et al. Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2016;27:1138-1142. PMID 26961150 — tags: [brain-metastases] — cited by: brain-metastases.md
• Gobbini E, et al. Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients. Bulletin du cancer. 2020;107:1098-1107. PMID 33032816 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Gogas HJ, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European journal of cancer (Oxford, England : 1990). 2019;119:97-106. PMID 31437754 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Goyal S, et al. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. JAMA oncology. 2015;1:668-76. PMID 26181286 — tags: [brain-metastases] — cited by: brain-metastases.md
• Grad RN, et al. Prognostic Risk Stratification and End-of-Life Care Outcomes in Patients With Metastatic Melanoma Treated With Immune Checkpoint Inhibitors. The oncologist. 2023;28:911-916. PMID 37543031 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Gupta M, et al. Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma. JAMA network open. 2023;6:e2319607. PMID 37351883 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Hadley CE, et al. Delayed and Concurrent Stereotactic Radiosurgery in Immunotherapy-Naïve Melanoma Brain Metastases. Cancers. 2024;16. PMID 39594689 — tags: [brain-metastases] — cited by: brain-metastases.md
• Heinzerling L, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO open. 2019;4:e000491. PMID 31231568 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Hong AM, et al. Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:3132-3141. PMID 31553661 — tags: [brain-metastases] — cited by: brain-metastases.md
• Hurst R, et al. Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated?. Journal of immunotherapy (Hagerstown, Md. : 1997). 1999;22:356-62. PMID 10404437 — tags: [brain-metastases] — cited by: brain-metastases.md
• Johnson DB, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. European journal of cancer (Oxford, England : 1990). 2015;51:2792-9. PMID 26608120 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Jones PS, et al. Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. Neurosurgical focus. 2015;38:E5. PMID 25727227 — tags: [brain-metastases] — cited by: brain-metastases.md
• Khattak A, et al. Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026;:JCO2600835. PMID 42223134 — tags: [cellular-therapy-and-resistance, clinical-trials-landscape] — cited by: cellular-therapy-and-resistance.md, clinical-trials-landscape.md
• Khoury S, et al. Durability of Complete Response to Intralesional Interleukin-2 for In-Transit Melanoma. Journal of cutaneous medicine and surgery. 2021;25:364-370. PMID 33529083 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Kluger HM, et al. Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development. Journal for immunotherapy of cancer. 2023;11. PMID 37487665 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Larkin J, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. The Lancet. Oncology. 2014;15:436-44. PMID 24582505 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Lim SY, et al. Single-cell RNA sequencing reveals melanoma cell state-dependent heterogeneity of response to MAPK inhibitors. EBioMedicine. 2024;107:105308. PMID 39216232 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Lin NU, et al. Response assessment criteria for brain metastases: proposal from the RANO group. The Lancet. Oncology. 2015;16:e270-8. PMID 26065612 — tags: [brain-metastases] — cited by: brain-metastases.md
• Lipson EJ, et al. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. European journal of cancer (Oxford, England : 1990). 2025;225:115547. PMID 40513285 — tags: [clinical-trials-landscape, immunotherapy-advanced-disease] — cited by: clinical-trials-landscape.md, immunotherapy-advanced-disease.md
• Lipson EJ, et al. Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047. Clinical cancer research : an official journal of the American Association for Cancer Research. 2025;31:3702-3714. PMID 40607902 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Long GV, et al. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. The Lancet. Oncology. 2025;26:320-330. PMID 39978375 — tags: [brain-metastases] — cited by: brain-metastases.md
• Lopci E. Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. Journal of clinical medicine. 2021;10. PMID 34768681 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Lyrarakis G, et al. Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition. Frontiers in oncology. 2024;14:1420879. PMID 39435288 — tags: [cellular-therapy-and-resistance, immunotherapy-advanced-disease] — cited by: cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md
• Mantia CM, et al. Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors. Melanoma research. 2022;32:35-44. PMID 34855329 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Maugeais M, et al. Impact of Liver Metastases and Number of Metastatic Sites on Immune-Checkpoint Inhibitors Efficacy in Patients with Different Solid Tumors: A Retrospective Study. Biomedicines. 2022;11. PMID 36672591 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• McGrail DJ, et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Annals of oncology : official journal of the European Society for Medical Oncology. 2021;32:661-672. PMID 33736924 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Nakano E, et al. Real-World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS-Mutant Melanoma: A Single-Center Retrospective Study in Japan. The Journal of dermatology. 2025;52:1897-1901. PMID 41059590 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Nardin C, et al. Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC). Cancers. 2023;15. PMID 37509227 — tags: [cellular-therapy-and-resistance, immunotherapy-advanced-disease] — cited by: cellular-therapy-and-resistance.md, immunotherapy-advanced-disease.md
• Persa OD, et al. Outcomes after retreatment with MAPK inhibitors and immune checkpoint inhibitors in melanoma patients. Future oncology (London, England). 2021;17:3809-3817. PMID 34254534 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Piperno-Neumann S, et al. Five-year survival with tebentafusp in metastatic uveal melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2026;37:1266-1277. PMID 42162665 — tags: [immunotherapy-advanced-disease, surveillance-and-survivorship, uveal-melanoma] — cited by: immunotherapy-advanced-disease.md, surveillance-and-survivorship.md, uveal-melanoma.md
• Pires da Silva I, et al. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment cell & melanoma research. 2019;32:553-563. PMID 30767428 — tags: [brain-metastases] — cited by: brain-metastases.md
• Powell S, et al. Single-institution outcome of high-dose interleukin-2 (HD IL-2) therapy for metastatic melanoma and analysis of favorable response in brain metastases. Anticancer research. 2009;29:4189-93. PMID 19846971 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Proietti I, et al. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review. Cancers. 2020;12. PMID 33003483 — tags: [cellular-therapy-and-resistance, targeted-therapy] — cited by: cellular-therapy-and-resistance.md, targeted-therapy.md
• Raizer JJ, et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro-oncology. 2008;10:199-207. PMID 18287337 — tags: [brain-metastases] — cited by: brain-metastases.md
• Regan MM, et al. Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. Journal for immunotherapy of cancer. 2025;13. PMID 40940136 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Regan MM, et al. Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. Journal for immunotherapy of cancer. 2021;9. PMID 34799400 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Regan MM, et al. Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:3350-3358. PMID 31498030 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Robert C, et al. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF(V600) mutation-positive melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2022;33:544-555. PMID 35131452 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Robert C, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England journal of medicine. 2019;381:626-636. PMID 31166680 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Rubin KM. MAPK Pathway-Targeted Therapies: Care and Management of Unique Toxicities in Patients With Advanced Melanoma. Clinical journal of oncology nursing. 2017;21:699-709. PMID 29149136 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Sarnaik AA, et al. Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39:2656-2666. PMID 33979178 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Schadendorf D, et al. COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma. European journal of cancer (Oxford, England : 1990). 2024;204:114073. PMID 38723373 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Schadendorf D, et al. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European journal of cancer (Oxford, England : 1990). 2021;153:234-241. PMID 34225229 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Serra F, et al. Treatment Following Progression in Metastatic Melanoma: the State of the Art from Scientific Literature to Clinical Need. Current oncology reports. 2021;23:84. PMID 34009481 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Shang Y, et al. BRAF inhibitor resistance in melanoma: from resistance mechanisms to therapeutic innovations. Molecular biomedicine. 2026;7. PMID 41807883 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Shanker MD, et al. Stereotactic radiosurgery for melanoma brain metastases: Concurrent immune checkpoint inhibitor therapy associated with superior clinicoradiological response outcomes. Journal of medical imaging and radiation oncology. 2022;66:536-545. PMID 35343063 — tags: [brain-metastases] — cited by: brain-metastases.md
• Sherman WJ, et al. Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases. Current treatment options in oncology. 2023;24:1962-1977. PMID 38158477 — tags: [brain-metastases] — cited by: brain-metastases.md
• Shimizu MR, et al. Incidence, Risk Factors, and Survival of Bone Metastases and Skeletal-Related Events in Melanoma Patients: A Systematic Review and Quality Assessment of 29 Studies. Journal of bone oncology. 2024;46:100603. PMID 38765703 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Shui IM, et al. Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions. Melanoma research. 2022;32:393-404. PMID 36223314 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Steeb T, et al. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. European journal of cancer (Oxford, England : 1990). 2021;157:348-357. PMID 34562816 — tags: [acral-and-mucosal-melanoma, targeted-therapy] — cited by: acral-and-mucosal-melanoma.md, targeted-therapy.md
• Steininger J, et al. Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment. International journal of molecular sciences. 2023;24. PMID 37511202 — tags: [brain-metastases] — cited by: brain-metastases.md
• Surendran HP, et al. Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis. Frontiers in oncology. 2026;16:1859306. PMID 42558559 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md
• Tang JD, et al. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery. Journal of neuro-oncology. 2024;166:431-440. PMID 38310157 — tags: [brain-metastases] — cited by: brain-metastases.md
• Tangella LP, et al. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review. Biochimica et biophysica acta. General subjects. 2021;1865:129736. PMID 32956754 — tags: [targeted-therapy] — cited by: targeted-therapy.md
• Tawbi HA, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. The Lancet. Oncology. 2021;22:1692-1704. PMID 34774225 — tags: [brain-metastases, clinical-trials-landscape, immunotherapy-advanced-disease, red-flags-and-safety-concerns] — cited by: brain-metastases.md, clinical-trials-landscape.md, immunotherapy-advanced-disease.md, red-flags-and-safety-concerns.md
• Teo JJ, et al. Novel treatment vs. standard of care in melanoma-associated leptomeningeal metastases: a systematic review and network meta-analysis. Chinese clinical oncology. 2025;14:4. PMID 40081385 — tags: [brain-metastases] — cited by: brain-metastases.md
• Thompson JF, et al. Radiation therapy for melanoma brain metastases: a systematic review. Radiology and oncology. 2022;56:267-284. PMID 35962952 — tags: [brain-metastases] — cited by: brain-metastases.md
• Tos SM, et al. Stereotactic Radiosurgery Dose Reduction for Melanoma Brain Metastases Patients on Immunotherapy or Target Therapy: A Single-Center Experience. Neurosurgery. 2025;96:1307-1320. PMID 39465916 — tags: [brain-metastases] — cited by: brain-metastases.md
• Tran AD, et al. Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial. PharmacoEconomics - open. 2022;6:587-594. PMID 35513735 — tags: [brain-metastases] — cited by: brain-metastases.md
• Tran AD, et al. Cost-Effectiveness of Subsequent Whole-Brain Radiotherapy or Hippocampal-Avoidant Whole-Brain Radiotherapy Versus Stereotactic Radiosurgery or Surgery Alone for Treatment of Melanoma Brain Metastases. Applied health economics and health policy. 2020;18:679-687. PMID 32157631 — tags: [brain-metastases] — cited by: brain-metastases.md
• Vera O, et al. A MAFG~MITF complex drives melanoma phenotype switching and progression. Nature communications. 2026;17. PMID 42168173 — tags: [cellular-therapy-and-resistance, targeted-therapy] — cited by: cellular-therapy-and-resistance.md, targeted-therapy.md
• Verger A, et al. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0. European journal of nuclear medicine and molecular imaging. 2025;52:1822-1839. PMID 39762634 — tags: [brain-metastases] — cited by: brain-metastases.md
• Wang J, et al. Surveillance for brain metastases in patients receiving systemic therapy for advanced melanoma. Melanoma research. 2014;24:54-60. PMID 24121189 — tags: [brain-metastases, surveillance-and-survivorship] — cited by: brain-metastases.md, surveillance-and-survivorship.md
• Wang Y, et al. Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III. European journal of cancer (Oxford, England : 1990). 2022;175:196-203. PMID 36137395 — tags: [brain-metastases] — cited by: brain-metastases.md
• Weber JS, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet (London, England). 2024;403:632-644. PMID 38246194 — tags: [cellular-therapy-and-resistance, clinical-trials-landscape] — cited by: cellular-therapy-and-resistance.md, clinical-trials-landscape.md
• Wegner RE, et al. Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome. Journal of neuro-oncology. 2021;152:79-87. PMID 33432380 — tags: [brain-metastases] — cited by: brain-metastases.md
• Wilcox JA, et al. Leptomeningeal Metastases: New Opportunities in the Modern Era. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2022;19:1782-1798. PMID 35790709 — tags: [brain-metastases] — cited by: brain-metastases.md
• Wilmott JS, et al. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clinical cancer research : an official journal of the American Association for Cancer Research. 2023;29:521-531. PMID 36477181 — tags: [brain-metastases] — cited by: brain-metastases.md
• Wolchok JD, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40:127-137. PMID 34818112 — tags: [immunotherapy-advanced-disease] — cited by: immunotherapy-advanced-disease.md
• Wroński M, et al. Surgical treatment of brain metastases from melanoma: a retrospective study of 91 patients. Journal of neurosurgery. 2000;93:9-18. PMID 10883899 — tags: [brain-metastases] — cited by: brain-metastases.md
• Zhang Y, et al. A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma. Cell reports. 2025;44:116675. PMID 41405996 — tags: [cellular-therapy-and-resistance, targeted-therapy] — cited by: cellular-therapy-and-resistance.md, targeted-therapy.md
• Zoroddu S, et al. Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies. Cells. 2025;14. PMID 41002441 — tags: [cellular-therapy-and-resistance] — cited by: cellular-therapy-and-resistance.md

Toxicity and safety

• Al Zein S. Immune Checkpoint Inhibitor-Induced Hypophysitis Presenting as Severe Hyponatremia: A Nephrology Perspective on Avoiding the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) Pitfall. Cureus. 2026;18:e109633. PMID 42359175 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Alekhina N, et al. Real-world management and outcomes of immune-mediated diarrhea and colitis: gaps in guideline adherence and opportunities for implementation. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2026;34. PMID 41902969 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Alexander A, et al. Metastatic melanoma in pregnancy: risk of transplacental metastases in the infant. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003;21:2179-86. PMID 12775744 — tags: [red-flags-and-safety-concerns, special-populations] — cited by: red-flags-and-safety-concerns.md, special-populations.md
• Allen WM, et al. Immune checkpoint inhibitor-induced myasthenia gravis and myocarditis: a fatal immune-related adverse event. Immunologic research. 2026;74. PMID 42384108 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Axelrod ML, et al. T cells specific for α-myosin drive immunotherapy-related myocarditis. Nature. 2022;611:818-826. PMID 36385524 — tags: [immune-related-adverse-events, red-flags-and-safety-concerns] — cited by: immune-related-adverse-events.md, red-flags-and-safety-concerns.md
• Bai R, et al. Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. Cancer biology & medicine. 2021;18:1118-33. PMID 34259422 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Blum SM, et al. Immune responses in checkpoint myocarditis across heart, blood and tumour. Nature. 2024;636:215-223. PMID 39506125 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Chitnis SD, et al. Clinical guideline highlights for the hospitalist: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. Journal of hospital medicine. 2023;18:1013-1016. PMID 37039096 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Curkovic NB, et al. Incidence of Cutaneous Immune-Related Adverse Events and Outcomes in Immune Checkpoint Inhibitor-Containing Regimens: A Systematic Review and Meta-Analysis. Cancers. 2024;16. PMID 38254829 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Da L, et al. Organ-Specific Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Monotherapy Versus Combination Therapy in Cancer: A Meta-Analysis of Randomized Controlled Trials. Frontiers in pharmacology. 2019;10:1671. PMID 32082164 — tags: [immune-related-adverse-events, red-flags-and-safety-concerns] — cited by: immune-related-adverse-events.md, red-flags-and-safety-concerns.md
• Das S, et al. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. Journal for immunotherapy of cancer. 2019;7:306. PMID 31730012 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Flatt N, et al. A composite score of serum cytokines enables early identification of patients at high risk for irAEs under immune checkpoint inhibition. Frontiers in immunology. 2025;16:1733357. PMID 41394871 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Gassenmaier M, et al. Diagnostic and prognostic classification of atypical spitzoid tumours based on histology and genomic aberrations: A prospective cohort study with long-term follow-up. European journal of cancer (Oxford, England : 1990). 2022;163:200-210. PMID 35104769 — tags: [red-flags-and-safety-concerns, special-populations] — cited by: red-flags-and-safety-concerns.md, special-populations.md
• Goodman RS, et al. Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma. JAMA network open. 2023;6:e2327145. PMID 37535354 — tags: [immune-related-adverse-events, red-flags-and-safety-concerns, surveillance-and-survivorship] — cited by: immune-related-adverse-events.md, red-flags-and-safety-concerns.md, surveillance-and-survivorship.md
• Gougis P, et al. Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective. EClinicalMedicine. 2024;70:102536. PMID 38560659 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Hawryluk EB, et al. Risk factors and outcomes of melanoma in children and adolescents: A retrospective multicenter study. Journal of the American Academy of Dermatology. 2024;90:716-726. PMID 38040338 — tags: [red-flags-and-safety-concerns, special-populations] — cited by: red-flags-and-safety-concerns.md, special-populations.md
• Hryniewicki AT, et al. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. The Journal of emergency medicine. 2018;55:489-502. PMID 30120013 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Husebye ES, et al. Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline. European journal of endocrinology. 2022;187:G1-G21. PMID 36149449 — tags: [guidelines, immune-related-adverse-events, red-flags-and-safety-concerns] — cited by: guidelines.md, immune-related-adverse-events.md, red-flags-and-safety-concerns.md
• Keith DJ, et al. Rate of positive diagnosis of skin cancer and its stage in two-week wait referrals in England according to age. Clinical and experimental dermatology. 2017;42:145-152. PMID 28044351 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Khan U, et al. Nivolumab induced myxedema crisis. Journal for immunotherapy of cancer. 2017;5:13. PMID 28239466 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Li C, et al. Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review. The western journal of emergency medicine. 2025;26:210-218. PMID 40145913 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Lipe DN, et al. Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review. Diagnostics (Basel, Switzerland). 2024;14. PMID 39202282 — tags: [immune-related-adverse-events, red-flags-and-safety-concerns] — cited by: immune-related-adverse-events.md, red-flags-and-safety-concerns.md
• Long B, et al. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. The western journal of emergency medicine. 2020;21:566-580. PMID 32421502 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Mytareli C, et al. The Uncharted Landscape of Rare Endocrine Immune-Related Adverse Events. Cancers. 2023;15. PMID 37046677 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Nielsen DL, et al. Immune checkpoint inhibitor-related neurotoxicity: Incidence and management. A systematic review and meta-analysis. Cancer treatment reviews. 2025;140:103011. PMID 40795646 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Saleem N, et al. Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis. JAMA oncology. 2025;11:1150-1159. PMID 40545616 — tags: [red-flags-and-safety-concerns, special-populations] — cited by: red-flags-and-safety-concerns.md, special-populations.md
• Salem JE, et al. Incidence and risk factors of immune checkpoint inhibitor myocardial and muscle toxicity: a French nationwide study. European heart journal. 2026;47:1014-1030. PMID 40884033 — tags: [immune-related-adverse-events, red-flags-and-safety-concerns] — cited by: immune-related-adverse-events.md, red-flags-and-safety-concerns.md
• Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021;39:4073-4126. PMID 34724392 — tags: [guidelines, immune-related-adverse-events, red-flags-and-safety-concerns] — cited by: guidelines.md, immune-related-adverse-events.md, red-flags-and-safety-concerns.md
• Spagnolo CC, et al. Immune checkpoint inhibitor-induced toxicity: a real-world analysis of the role of BMI. Frontiers in oncology. 2025;15:1659977. PMID 41278286 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Spain L, et al. Management of toxicities of immune checkpoint inhibitors. Cancer treatment reviews. 2016;44:51-60. PMID 26874776 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Suo A, et al. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma. The oncologist. 2020;25:438-446. PMID 32048768 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Teijeira L, et al. Baseline Circulating Blood Cell Counts and Ratios and Changes Therein for Predicting Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy: A Multicenter, Prospective, Observational, Pan-Cancer Cohort Study with a Gender Perspective. Cancers. 2023;16. PMID 38201577 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Thu AN, et al. Life-Threatening Secondary Adrenal Crisis Triggered by Pembrolizumab-Induced Hypophysitis: A Case Report. Cureus. 2026;18:e111692. PMID 42528939 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md
• Tocchetti CG, et al. Cardiovascular toxicities of immune therapies for cancer - a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. European journal of heart failure. 2024;26:2055-2076. PMID 39087551 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Torino F, et al. Endocrinological side-effects of immune checkpoint inhibitors. Current opinion in oncology. 2016;28:278-87. PMID 27136136 — tags: [immune-related-adverse-events] — cited by: immune-related-adverse-events.md
• Verheijden RJ, et al. Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024;42:3713-3724. PMID 39110922 — tags: [immune-related-adverse-events, red-flags-and-safety-concerns] — cited by: immune-related-adverse-events.md, red-flags-and-safety-concerns.md
• Wang DY, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA oncology. 2018;4:1721-1728. PMID 30242316 — tags: [immune-related-adverse-events, red-flags-and-safety-concerns] — cited by: immune-related-adverse-events.md, red-flags-and-safety-concerns.md
• Wright JJ, et al. Approach to the Patient With Immune Checkpoint Inhibitor-Associated Endocrine Dysfunction. The Journal of clinical endocrinology and metabolism. 2023;108:1514-1525. PMID 36481794 — tags: [red-flags-and-safety-concerns] — cited by: red-flags-and-safety-concerns.md

Non-cutaneous and special-population melanoma

• Abdel-Wahab N, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. Journal for immunotherapy of cancer. 2019;7:106. PMID 30992053 — tags: [special-populations] — cited by: special-populations.md
• Abdullayeva L. Donor-Transmitted Melanoma: Is It Still Bothering Us?. Current treatment options in oncology. 2020;21:38. PMID 32328846 — tags: [special-populations] — cited by: special-populations.md
• Bannister-Tyrrell M, et al. Incidence and outcomes of pregnancy-associated melanoma in New South Wales 1994-2008. The Australian & New Zealand journal of obstetrics & gynaecology. 2015;55:116-22. PMID 25349945 — tags: [special-populations] — cited by: special-populations.md
• Bartenstein DW, et al. Clinical features and outcomes of spitzoid proliferations in children and adolescents. The British journal of dermatology. 2019;181:366-372. PMID 30467833 — tags: [special-populations] — cited by: special-populations.md
• Bethlehem MS, et al. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. Cancers. 2021;13. PMID 34572953 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Bol KF, et al. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. Cancers. 2019;11. PMID 31623302 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Borad A, et al. Pediatric Melanoma: Geographic Trends in Incidence, Stage, and Mortality in the United States. The Journal of surgical research. 2023;290:215-220. PMID 37285703 — tags: [special-populations] — cited by: special-populations.md
• Bordeanu-Diaconescu EM, et al. Comprehensive Literature Review on Melanoma of Unknown Primary Site Triggered by an Intriguing Case Report. Diagnostics (Basel, Switzerland). 2024;14. PMID 39410614 — tags: [special-populations] — cited by: special-populations.md
• Boussios S, et al. Melanoma of unknown primary: New perspectives for an old story. Critical reviews in oncology/hematology. 2021;158:103208. PMID 33383207 — tags: [special-populations] — cited by: special-populations.md
• Braga A, et al. Cancer in Pregnancy: Therapeutic Decisions at the Intersection of Two Lives. Diagnostics (Basel, Switzerland). 2026;16. PMID 41975782 — tags: [special-populations] — cited by: special-populations.md
• Carter TM, et al. Does acral lentiginous melanoma subtype account for differences in patterns of care in Black patients?. American journal of surgery. 2021;221:706-711. PMID 33461732 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Chandrasekhar S, et al. Troponin Elevation in Patients Undergoing Percutaneous Hepatic Perfusion for Metastatic Uveal Melanoma. Cancer control : journal of the Moffitt Cancer Center. 2024;31:10732748241246898. PMID 38605434 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Chang RC, et al. Treatment and survival disparities in acral lentiginous melanoma: a National Cancer Database multivariate analysis. Melanoma research. 2025;35:409-417. PMID 40773363 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Choudhary MM, et al. Hepatic Ultrasonography for Surveillance in Patients With Uveal Melanoma. JAMA ophthalmology. 2016;134:174-80. PMID 26633182 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Cook MR, et al. Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review. JAMA oncology. 2019;5:1049-1054. PMID 30730549 — tags: [special-populations] — cited by: special-populations.md
• Dalmau J, et al. Acral melanoma simulating warts: dermoscopic clues to prevent missing a melanoma. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2006;32:1072-8. PMID 16918571 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Danysh HE, et al. Malignant melanoma incidence among children and adolescents in Texas and SEER 13, 1995-2013. Pediatric blood & cancer. 2019;66:e27648. PMID 30729662 — tags: [special-populations] — cited by: special-populations.md
• de Givry AC, et al. Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study. The oncologist. 2025;31. PMID 41396687 — tags: [special-populations] — cited by: special-populations.md
• de Melo AC, et al. Frequency of HLA-A*02:01 in the Brazilian population and its impact on uveal melanoma systemic treatment. The oncologist. 2024;29:e1098-e1099. PMID 38785402 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Desai A, et al. Acral melanoma foot lesions. Part 2: clinical presentation, diagnosis, and management. Clinical and experimental dermatology. 2018;43:117-123. PMID 29235153 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Dogrusöz M, et al. Uveal Melanoma Treatment and Prognostication. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2017;6:186-196. PMID 28399342 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Fariyike O, et al. Understanding acral lentiginous melanoma: from the clinic to guidelines. Clinical and experimental dermatology. 2026;51:967-976. PMID 41219165 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Fletcher K, et al. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study. Cancer letters. 2024;596:217001. PMID 38838764 — tags: [special-populations] — cited by: special-populations.md
• Furney SJ, et al. The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis. Pigment cell & melanoma research. 2014;27:835-8. PMID 24913711 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Garcia LC, et al. Plantar acral melanoma: epidemiological, clinical, dermoscopic and histopathological features. A Brazilian cohort. Anais brasileiros de dermatologia. 2025;100:45-53. PMID 39616094 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Ghali H, et al. Hepatic and Overall Progression-Free Survival After Percutaneous Hepatic Perfusion (PHP) as First-Line or Second-Line Therapy for Metastatic Uveal Melanoma. Annals of surgical oncology. 2024;31:9150-9158. PMID 39174837 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Gil-Pallares P, et al. Reconstruction of plantar surgical defects with synthetic dermal matrix and split-thickness skin grafts: A case series and functional podiatry outcomes. The Australasian journal of dermatology. 2023;64:e357-e360. PMID 37724606 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Gill VT, et al. Threshold analysis of mortality outcomes in the collaborative ocular melanoma study (COMS). Melanoma management. 2025;12:2494977. PMID 40323297 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Grant S, et al. Disparities in acral lentiginous melanoma: Factors beyond delayed diagnosis. Journal of the American Academy of Dermatology. 2025;93:1018-1026. PMID 40562077 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Haddock NT, et al. Wide local en bloc excision of subungual melanoma in situ. Annals of plastic surgery. 2014;73:640-4. PMID 24322643 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Han B, et al. Acral lentiginous melanoma in situ: dermoscopic features and management strategy. Scientific reports. 2020;10:20503. PMID 33239715 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods in molecular biology (Clifton, N.J.). 2014;1102:427-40. PMID 24258991 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Hassel JC, et al. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma. The New England journal of medicine. 2023;389:2256-2266. PMID 37870955 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Hawkins BS. Collaborative ocular melanoma study randomized trial of I-125 brachytherapy. Clinical trials (London, England). 2011;8:661-73. PMID 22013172 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Huang K, et al. Acral Lentiginous Melanoma: Incidence and Survival in the United States, 2006-2015, an Analysis of the SEER Registry. The Journal of surgical research. 2020;251:329-339. PMID 32208196 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Ingrassia JP, et al. Diagnosis and Management of Acral Pigmented Lesions. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2023;49:926-931. PMID 37556446 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Isaq NA, et al. Dermatologic surgeons' approaches to acral lentiginous melanoma: a survey of the American College of Mohs Surgery. Archives of dermatological research. 2023;316:17. PMID 38059993 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Ishihara Y, et al. Early acral melanoma in situ: correlation between the parallel ridge pattern on dermoscopy and microscopic features. The American Journal of dermatopathology. 2006;28:21-7. PMID 16456320 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Johnson DB, et al. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123:1904-1911. PMID 28241095 — tags: [special-populations] — cited by: special-populations.md
• Joshi K, et al. Immunotherapy Outcomes in Advanced Melanoma in Relation to Age. The Permanente journal. 2020;24. PMID 32097116 — tags: [special-populations] — cited by: special-populations.md
• Khazzaka A, et al. Systematic review of fetal and placental metastases among pregnant patients with cancer. Cancer treatment reviews. 2022;104:102356. PMID 35182890 — tags: [special-populations] — cited by: special-populations.md
• Kim J, et al. Foot Melanoma Reconstruction Using a Refined Perforator Flap: Safety, Function, and Subregional Surgical Strategy. Plastic and reconstructive surgery. 2026;158:491e-499e. PMID 41294367 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Kolb M, et al. Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for Metastasized Uveal Melanoma: A Retrospective Comparative Study. Cancers. 2023;15. PMID 37894309 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Koopmans AE, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2014;27:1321-30. PMID 24633195 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Kumar R, et al. Safety of immune checkpoint inhibitors in patients with preexisting autoimmune disorders. Current problems in cancer. 2022;46:100864. PMID 35671576 — tags: [special-populations] — cited by: special-populations.md
• Li S, et al. Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis. Journal for immunotherapy of cancer. 2022;10. PMID 35193932 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Lian B, et al. Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2024;35:211-220. PMID 37956739 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Lodde G, et al. Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma. The British journal of dermatology. 2026;194:843-853. PMID 41719057 — tags: [special-populations] — cited by: special-populations.md
• Maker AV, et al. Closure of Melanoma Defects on the Sole of the Foot Using Glaborous Skin: The End of the Flap?. Annals of surgical oncology. 2015;22:4081-2. PMID 25749930 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Margo CE. The Collaborative Ocular Melanoma Study: an overview. Cancer control : journal of the Moffitt Cancer Center. 2004;11:304-9. PMID 15377989 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Melia M, et al. Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Archives of ophthalmology (Chicago, Ill. : 1960). 2006;124:226-38. PMID 16476893 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Mendizábal E, et al. Maternal and perinatal outcomes in pregnancy-associated melanoma. Report of two cases and a systematic literature review. European journal of obstetrics, gynecology, and reproductive biology. 2017;214:131-139. PMID 28527349 — tags: [special-populations] — cited by: special-populations.md
• Mies G, et al. Meta-analysis of uveal melanoma genome-wide association studies identifies novel risk loci and population effect size heterogeneity. HGG advances. 2025;6:100465. PMID 40495383 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Moore-Olufemi S, et al. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Annals of surgery. 2011;253:1211-5. PMID 21451389 — tags: [special-populations] — cited by: special-populations.md
• Morecroft R, et al. Immunoembolization in liver-predominant metastatic uveal melanoma: a single-center retrospective analysis. Frontiers in oncology. 2026;16:1752725. PMID 42109660 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Nijran A, et al. Evaluation of Paediatric Melanoma Management in a UK Major Tertiary Centre: A Twenty-Year Review. Cureus. 2025;17:e89649. PMID 40926920 — tags: [special-populations] — cited by: special-populations.md
• Park CK, et al. Melanoma incidence, stage, and survival after solid organ transplant: A population-based cohort study in Ontario, Canada. Journal of the American Academy of Dermatology. 2020;83:754-761. PMID 32111554 — tags: [special-populations] — cited by: special-populations.md
• Park HK, et al. Comparative Whole-Genome Sequencing Analysis of In-situ and Invasive Acral Lentiginous Melanoma: Markedly Increased Copy Number Gains of GAB2 , PAK1 , UCP2 , and CCND1 are Associated with Melanoma Invasion. The American journal of surgical pathology. 2024;48:1061-1071. PMID 38916228 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Peacker BL, et al. Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations. Advances in therapy. 2026;43:551-566. PMID 41461997 — tags: [special-populations] — cited by: special-populations.md
• Persa OD, et al. Brief Communication: Treatment Outcomes for Advanced Melanoma of Unknown Primary Compared With Melanoma With Known Primary. Journal of immunotherapy (Hagerstown, Md. : 1997). 2024;47:384-387. PMID 39206786 — tags: [special-populations] — cited by: special-populations.md
• Pierro M, et al. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. Cancers. 2022;14. PMID 36291861 — tags: [special-populations] — cited by: special-populations.md
• Portuguese AJ, et al. Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review. Journal of the National Comprehensive Cancer Network : JNCCN. 2022;20:406-416.e11. PMID 35390767 — tags: [special-populations] — cited by: special-populations.md
• Rantala ES, et al. Hepatic Ultrasonography Compared With Computed Tomography and Magnetic Resonance Imaging at Diagnosis of Metastatic Uveal Melanoma. American journal of ophthalmology. 2020;216:156-164. PMID 32278769 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Ravaioli GM, et al. Acral melanoma: correlating the clinical presentation to the mutational status. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia. 2019;154:567-572. PMID 29512974 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Riechardt AI, et al. Salvage proton beam therapy in local recurrent uveal melanoma. American journal of ophthalmology. 2014;158:948-56. PMID 25038327 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Robertson AG, et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer cell. 2017;32:204-220.e15. PMID 28810145 — tags: [patient-experience-and-advocacy, uveal-melanoma] — cited by: patient-experience-and-advocacy.md, uveal-melanoma.md
• Sacco JJ, et al. Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for immunotherapy of cancer. 2024;12. PMID 38844408 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Sheng X, et al. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:2987-2999. PMID 31403867 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Slavkova ST, et al. When two lives intersect: melanoma in pregnancy: mechanisms, risks, and management strategies. Contemporary oncology (Poznan, Poland). 2026;30:7-12. PMID 42089033 — tags: [special-populations] — cited by: special-populations.md
• Song Y, et al. Melanoma of unknown primary. Journal of surgical oncology. 2019;119:232-241. PMID 30481368 — tags: [special-populations] — cited by: special-populations.md
• Sureda N, et al. Conservative surgical management of subungual (matrix derived) melanoma: report of seven cases and literature review. The British journal of dermatology. 2011;165:852-8. PMID 21812768 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Tan B, et al. Acute renal transplant rejection following nivolumab therapy for metastatic melanoma. BMJ case reports. 2021;14. PMID 33558380 — tags: [special-populations] — cited by: special-populations.md
• Tang B, et al. Five-Year Follow-Up of POLARIS-01 Phase II Trial: Toripalimab as Salvage Monotherapy in Chinese Patients With Advanced Melanoma. The oncologist. 2024;29:e822-e827. PMID 38547052 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Tang S, et al. Single cell RNA-sequencing in uveal melanoma: advances in heterogeneity, tumor microenvironment and immunotherapy. Frontiers in immunology. 2024;15:1427348. PMID 38966635 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Tupper CJ, et al. Improved survival outcomes for melanoma of unknown primary in the era of novel therapies: A population-based retrospective analysis. Journal of the American Academy of Dermatology. 2024;91:111-113. PMID 38458569 — tags: [special-populations] — cited by: special-populations.md
• Utter K, et al. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology. 2017;93:249-258. PMID 28746931 — tags: [special-populations] — cited by: special-populations.md
• van den Hoek L, et al. Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial. The Lancet. Oncology. 2026;27:372-382. PMID 41785896 — tags: [clinical-trials-landscape, uveal-melanoma] — cited by: clinical-trials-landscape.md, uveal-melanoma.md
• van Essen TH, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. The British journal of ophthalmology. 2014;98:1738-43. PMID 25147369 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Venkatachalam K, et al. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients. Transplantation. 2020;104:1041-1047. PMID 31415036 — tags: [special-populations] — cited by: special-populations.md
• Verma V, et al. Clinical Outcomes of Proton Radiotherapy for Uveal Melanoma. Clinical oncology (Royal College of Radiologists (Great Britain)). 2016;28:e17-27. PMID 26915706 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Watt KD, et al. Safety of immunotherapy after liver transplantation-A multicenter study of a prospective standardized clinical practice protocol. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2026;32:685-692. PMID 41082711 — tags: [special-populations] — cited by: special-populations.md
• Won SH, et al. Dermoscopic Features of Subcorneal Hematoma on the Palms and Soles: Differences from Acral Melanoma. Acta dermatovenerologica Croatica : ADC. 2023;31:192-197. PMID 38651845 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Woo SJ, et al. Serratus Anterior Fascia Free Flap for Functional Surgery of Subungual Melanoma: Case Series and Literature Review. Archives of plastic surgery. 2025;52:90-95. PMID 40083617 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md
• Wu HT, et al. Pregnancy and survival-related outcomes of uveal melanoma treated with brachytherapy in women of reproductive age. BMC ophthalmology. 2024;24:416. PMID 39333941 — tags: [special-populations] — cited by: special-populations.md
• Xu X, et al. A Multistep Immune-Competent Genetically Engineered Mouse Model Reveals Phenotypic Plasticity in Uveal Melanoma. Cancer research. 2026;86:3666-3686. PMID 41661679 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Zabor EC, et al. Systemic surveillance for uveal melanoma: Approach to optimization. PloS one. 2026;21:e0355405. PMID 42616744 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Zager JS, et al. An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma. Annals of surgical oncology. 2025;32:4976-4988. PMID 40192993 — tags: [uveal-melanoma] — cited by: uveal-melanoma.md
• Zhang F, et al. Genomic characterization reveals distinct mutational landscape of acral melanoma in East Asian. Journal of genetics and genomics = Yi chuan xue bao. 2025;52:525-538. PMID 39798666 — tags: [acral-and-mucosal-melanoma] — cited by: acral-and-mucosal-melanoma.md

Surveillance, survivorship and patient experience

• Lee R, et al. Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial. Nature communications. 2026;17:6850. PMID 42168180 — tags: [clinical-trials-landscape, surveillance-and-survivorship] — cited by: clinical-trials-landscape.md, surveillance-and-survivorship.md
• Williams HC, et al. Evaluation of public education campaigns in cutaneous melanoma: the King's College Hospital experience. The British journal of dermatology. 1990;123:85-92. PMID 2390498 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md

• Mercado S, et al. Effectiveness of cross-sector collaboration in strategy implementation and impact: Evaluation of the NSW Skin Cancer Prevention Strategy 2016-2022. Health promotion journal of Australia. 2025;36:e934. PMID 39663828 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md

• Amaral T, et al. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2025;36:10-30. PMID 39550033 — tags: [guidelines, surveillance-and-survivorship] — cited by: guidelines.md, surveillance-and-survivorship.md

• Askew RL, et al. Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2011;14:900-6. PMID 21914512 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Bath-Hextall F, et al. The needs and experiences of patients with skin cancer: a qualitative systematic review with metasynthesis. The British journal of dermatology. 2017;177:666-687. PMID 27775838 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Boulanger MC, et al. Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative Study. JCO oncology practice. 2025;21:178-187. PMID 39038253 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Brown SL, et al. Fear of cancer recurrence and adverse cancer treatment outcomes: predicting 2- to 5-year fear of recurrence from post-treatment symptoms and functional problems in uveal melanoma survivors. Journal of cancer survivorship : research and practice. 2023;17:187-196. PMID 34850324 — tags: [patient-experience-and-advocacy, surveillance-and-survivorship] — cited by: patient-experience-and-advocacy.md, surveillance-and-survivorship.md
• Brown SL, et al. Seven-year distress trajectories in uveal melanoma survivors. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2023;42:247-256. PMID 36848060 — tags: [patient-experience-and-advocacy, surveillance-and-survivorship] — cited by: patient-experience-and-advocacy.md, surveillance-and-survivorship.md
• Brunsgaard EK, et al. Feasibility of personalized circulating tumor DNA detection in stage II and III melanoma. Melanoma research. 2023;33:184-191. PMID 37040662 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Chernyshov PV, et al. Quality of life measurement in skin cancer patients: literature review and position paper of the European Academy of Dermatology and Venereology Task Forces on Quality of Life and Patient Oriented Outcomes, Melanoma and Non-Melanoma Skin Cancer. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019;33:816-827. PMID 30963614 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Dieng M, et al. Patients' Views About Skin Self-examination After Treatment for Localized Melanoma. JAMA dermatology. 2019;155:914-921. PMID 31090868 — tags: [patient-experience-and-advocacy, surveillance-and-survivorship] — cited by: patient-experience-and-advocacy.md, surveillance-and-survivorship.md
• Dieng M, et al. Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma. JAMA dermatology. 2018;154:52-59. PMID 29188268 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Dieng M, et al. The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma. Annals of surgical oncology. 2022;29:2871-2881. PMID 35142966 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Eroglu Z, et al. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Cancer. 2023;129:1723-1734. PMID 36869646 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Fenton GL, et al. Exploring the emotional and behavioural reactions to receiving personalized melanoma genomic risk information: a qualitative study. The British journal of dermatology. 2019;180:1390-1396. PMID 30580464 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Fox JA, et al. Palliative care in the context of immune and targeted therapies: A qualitative study of bereaved carers' experiences in metastatic melanoma. Palliative medicine. 2020;34:1351-1360. PMID 32338133 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Fox JA, et al. Uncertain diagnosis and prognosis in advanced melanoma: a qualitative study of the experiences of bereaved carers in a time of immune and targeted therapies. The British journal of dermatology. 2019;180:1368-1376. PMID 30515757 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Fu H, et al. Supportive care and unmet needs in patients with melanoma: a mixed-methods systematic review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020;28:3489-3501. PMID 32342223 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Gautron Moura B, et al. Estimated Costs of the Ipilimumab-Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers. 2022;15. PMID 36612030 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Geidel G, et al. Translating ctDNA into cutaneous melanoma care: An international expert survey. European journal of cancer (Oxford, England : 1990). 2026;239:116676. PMID 41932032 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Hansen SM, et al. Employing skin self-examination and fear of cancer recurrence management in early-stage melanoma follow-up: evaluation of the MELACARE intervention in a randomised controlled trial. Journal of cancer survivorship : research and practice. 2025;. PMID 40504479 — tags: [patient-experience-and-advocacy, surveillance-and-survivorship] — cited by: patient-experience-and-advocacy.md, surveillance-and-survivorship.md
• Higham CE, et al. Adjuvant immunotherapy: the sting in the tail. European journal of cancer (Oxford, England : 1990). 2020;132:207-210. PMID 32388064 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Lamprell K, et al. When Patients Tell Their Own Stories: A Meta-Narrative Study of Web-Based Personalized Texts of 214 Melanoma Patients' Journeys in Four Countries. Qualitative health research. 2018;28:1564-1583. PMID 29173015 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Liu ZF, et al. Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis. American journal of clinical dermatology. 2024;25:513-525. PMID 38635019 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Lleshi K, et al. Impact on Quality of Life and Psychological Dimensions in Caregivers of Melanoma and Sarcoma Patients: A Scoping Review. Cancers. 2026;18. PMID 41827744 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Mahama AN, et al. Lived Experiences and Fear of Cancer Recurrence Among Survivors of Localized Cutaneous Melanoma. JAMA dermatology. 2024;160:495-501. PMID 38353983 — tags: [patient-experience-and-advocacy, surveillance-and-survivorship] — cited by: patient-experience-and-advocacy.md, surveillance-and-survivorship.md
• Manne SL, et al. mySmartCheck, a Digital Intervention to Promote Skin Self-examination Among Individuals Diagnosed With or at Risk for Melanoma: A Randomized Clinical Trial. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine. 2022;56:791-803. PMID 34637495 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Moncrieff MD, et al. Follow-up Schedule for Patients With Sentinel Node-negative Cutaneous Melanoma (The MELFO Study): An International Phase III Randomized Clinical Trial. Annals of surgery. 2022;276:e208-e216. PMID 35866644 — tags: [guidelines, patient-experience-and-advocacy, surveillance-and-survivorship] — cited by: guidelines.md, patient-experience-and-advocacy.md, surveillance-and-survivorship.md
• Müller A, et al. [How do doctors communicate results of genomic testing and its prognostic impact on uveal melanoma patients? Results of a qualitative study]. Bulletin du cancer. 2026;113:165-174. PMID 41203514 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Müller A, et al. Anxiety, depression and fear of cancer recurrence in uveal melanoma survivors and ophthalmologist/oncologist communication during survivorship in France - protocol of a prospective observational mixed-method study. BMC psychiatry. 2024;24:812. PMID 39548476 — tags: [patient-experience-and-advocacy, surveillance-and-survivorship] — cited by: patient-experience-and-advocacy.md, surveillance-and-survivorship.md
• Ni Y, et al. Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort. The British journal of dermatology. 2023;188:814-816. PMID 36946230 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Noorda EM, et al. The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2007;33:776-82. PMID 17300914 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Obinah MPB, et al. Circulating tumor DNA for surveillance in high-risk melanoma patients: a study protocol. Acta oncologica (Stockholm, Sweden). 2025;64:229-233. PMID 39930781 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Ochenduszko S, et al. Adjuvant anti-PD1 immunotherapy of resected skin melanoma: an example of non-personalized medicine with no overall survival benefit. Critical reviews in oncology/hematology. 2024;202:104443. PMID 39025250 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Palacios-Diaz RD, et al. Circulating tumor DNA predicts tumor progression and poor survival in patients with stage III melanoma. Melanoma research. 2025;35:259-267. PMID 40387867 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Patel VR, et al. Risk of Mortality After a Diagnosis of Melanoma In Situ. JAMA dermatology. 2023;159:703-710. PMID 37285145 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Reinhardt ME, et al. A systematic review of patient-reported outcome measures for advanced skin cancer patients. Archives of dermatological research. 2023;315:1473-1480. PMID 36469125 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Robinson JK, et al. Early Detection of New Melanomas by Patients With Melanoma and Their Partners Using a Structured Skin Self-examination Skills Training Intervention: A Randomized Clinical Trial. JAMA dermatology. 2016;152:979-85. PMID 27367303 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Robinson JK, et al. Remote skin self-examination training of melanoma survivors and their skin check partners: A randomized trial and comparison with in-person training. Cancer medicine. 2020;9:7301-7309. PMID 32761987 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Robinson JK, et al. Skin self-examination education for early detection of melanoma: a randomized controlled trial of Internet, workbook, and in-person interventions. Journal of medical Internet research. 2014;16:e7. PMID 24418949 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Schroeder C, et al. Tumour-informed liquid biopsies to monitor advanced melanoma patients under immune checkpoint inhibition. Nature communications. 2024;15:8750. PMID 39384805 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Swartz RJ, et al. Reducing patient burden to the FACT-Melanoma quality-of-life questionnaire. Melanoma research. 2012;22:158-63. PMID 22395418 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md
• Thom B, et al. The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. Journal of psychosocial oncology. 2021;39:285-293. PMID 33103948 — tags: [patient-experience-and-advocacy, surveillance-and-survivorship] — cited by: patient-experience-and-advocacy.md, surveillance-and-survivorship.md
• Tie J, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nature medicine. 2025;31:1509-1518. PMID 40055522 — tags: [surveillance-and-survivorship] — cited by: surveillance-and-survivorship.md
• Winstanley JB, et al. The FACT-Melanoma quality-of-life instrument: comparison of a five-point and four-point response scale using the Rasch measurement model. Melanoma research. 2013;23:61-9. PMID 23262441 — tags: [patient-experience-and-advocacy] — cited by: patient-experience-and-advocacy.md

Guidelines and trials landscape

• Gonzalez-Cao M, et al. Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM). Journal for immunotherapy of cancer. 2021;9:e001664. PMID 33782108 — tags: [guidelines] — cited by: guidelines/REGISTRY.md
• Crisan D, et al. Surgical treatment of melanoma in pregnancy: a practical guideline. Journal der Deutschen Dermatologischen Gesellschaft. 2016;14:585-593. PMID 27240064 — tags: [guidelines] — cited by: guidelines/REGISTRY.md
• Dummer R, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2012;23 Suppl 7:vii86-91. PMID 22997461 — tags: [guidelines] — cited by: guidelines/REGISTRY.md
• Dummer R, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology. 2015;26 Suppl 5:v126-32. PMID 26314774 — tags: [guidelines] — cited by: guidelines/REGISTRY.md
• Skalicky SE, et al. Australian Cancer Network clinical practice guidelines for the management of ocular and periocular melanoma: an evidence-based literature analysis. Clinical & experimental ophthalmology. 2008;36:646-58. PMID 18983550 — tags: [guidelines] — cited by: guidelines/REGISTRY.md
• Scolyer RA, et al. Improving diagnostic accuracy for suspicious melanocytic skin lesions: New Australian melanoma clinical practice guidelines stress the importance of clinician/pathologist communication. Australian journal of general practice. 2019;48:357-362. PMID 31220881 — tags: [guidelines] — cited by: guidelines/REGISTRY.md

• Jiménez-Requena F, et al. Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma. European journal of nuclear medicine and molecular imaging. 2010;37:284-300. PMID 19727717 — tags: [staging, statistics] — cited by: staging.md, statistics/STATISTICS.md

• Adler NR, et al. Methods of melanoma detection and of skin monitoring for individuals at high risk of melanoma: new Australian clinical practice. The Medical journal of Australia. 2019;210:41-47. PMID 30636296 — tags: [guidelines] — cited by: guidelines.md

• Fukushima S, et al. Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Melanoma 2025. The Journal of dermatology. 2025;52:e666-e697. PMID 40511899 — tags: [guidelines] — cited by: guidelines.md
• Guo J, et al. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Annals of translational medicine. 2015;3:322. PMID 26734632 — tags: [guidelines] — cited by: guidelines.md
• Guo J, et al. Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chinese clinical oncology. 2016;5:57. PMID 27164849 — tags: [guidelines] — cited by: guidelines.md
• Gyorki DE, et al. When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the 'Australian guidelines for the management of cutaneous melanoma'. The Australasian journal of dermatology. 2017;58:274-277. PMID 28718222 — tags: [guidelines] — cited by: guidelines.md
• Keohane SG, et al. The new 8th edition of TNM staging and its implications for skin cancer: a review by the British Association of Dermatologists and the Royal College of Pathologists, U.K. The British journal of dermatology. 2018;179:824-828. PMID 29923189 — tags: [guidelines] — cited by: guidelines.md
• Marsden JR, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. The British journal of dermatology. 2010;163:238-56. PMID 20608932 — tags: [guidelines] — cited by: guidelines.md
• Marsden JR, et al. Revised UK guidelines for the management of cutaneous melanoma 2010. Journal of plastic, reconstructive & aesthetic surgery : JPRAS. 2010;63:1401-19. PMID 20728418 — tags: [guidelines] — cited by: guidelines.md
• Michielin O, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of oncology : official journal of the European Society for Medical Oncology. 2019;30:1884-1901. PMID 31566661 — tags: [guidelines] — cited by: guidelines.md
• Nakamura Y, et al. Japanese Dermatological Association Guidelines: Outlines of guidelines for cutaneous melanoma 2019. The Journal of dermatology. 2020;47:89-103. PMID 31782186 — tags: [guidelines] — cited by: guidelines.md
• Piperno-Neumann S, et al. Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO open. 2026;11:106888. PMID 42020098 — tags: [guidelines] — cited by: guidelines.md
• Roberts DL, et al. U.K. guidelines for the management of cutaneous melanoma. The British journal of dermatology. 2002;146:7-17. PMID 11841361 — tags: [guidelines] — cited by: guidelines.md
• Soft Tissue Tumor and Melanoma Group of Sarcoma Committee, Chinese Anti-Cancer Association. [Chinese expert consensus on the surgical treatment of cutaneous/acral melanoma V1.0]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2020;42:81-93. PMID 32135640 — tags: [guidelines] — cited by: guidelines.md

Most-cited records

PMID	Citation	Pages citing
28591523	Faries MB, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. The New England journal of medicine. 2017;376:2211-2222	8
39700658	Garbe C, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024. European journal of cancer (Oxford, England : 1990). 2025;215:115152	8
37071089	Mangione CM, et al. Screening for Skin Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329:1290-1295	7
29028110	Gershenwald JE, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: a cancer journal for clinicians. 2017;67:472-492	6
38828984	Blank CU, et al. Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma. The New England journal of medicine. 2024;391:1696-1708	6
35293957	Adamson AS, et al. Estimating Overdiagnosis of Melanoma Using Trends Among Black and White Patients in the US. JAMA dermatology. 2022;158:426-431	5
35533771	Brunsgaard EK, et al. Melanoma in skin of color: Part I. Epidemiology and clinical presentation. Journal of the American Academy of Dermatology. 2023;89:445-456	5
36166727	Atkins MB, et al. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2023;41:186-197	5
36856617	Patel SP, et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. The New England journal of medicine. 2023;388:813-823	5
39282897	Wolchok JD, et al. Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. The New England journal of medicine. 2025;392:11-22	5
40198940	Luke JJ, et al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. European journal of cancer (Oxford, England : 1990). 2025;220:115381	5
24272143	Bishop KD, et al. Epidemiology and survival outcomes of ocular and mucosal melanomas: a population-based analysis. International journal of cancer. 2014;134:2961-71	4
26091043	Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell. 2015;161:1681-96	4
29402264	Zager JS, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC cancer. 2018;18:130	4
29746316	Gong HZ, et al. The clinical significance of KIT mutations in melanoma: a meta-analysis. Melanoma research. 2018;28:259-270	4
31401470	Kanaki T, et al. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma. European journal of cancer (Oxford, England : 1990). 2019;119:18-29	4
31557067	Leiter U, et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:3000-3008	4
33764387	Patrinely JR Jr, et al. Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA oncology. 2021;7:744-748	4
34153328	Kleinerman RA, et al. Increased Risk of Skin Cancer in 1,851 Long-Term Retinoblastoma Survivors. The Journal of investigative dermatology. 2021;141:2849-2857.e3	4
34363907	Yan BY, et al. Survival differences in acral lentiginous melanoma according to socioeconomic status and race. Journal of the American Academy of Dermatology. 2022;86:379-386	4